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University of Connecticut, 2017 
 
Abstract 
Antibiotic resistance is an ever-present problem that reduces the arsenal of 
antibiotics human’s possess to fight pathogenic infections.  New generations of 
antibiotics are therefore always required.  Recent history has seen few novel classes 
of antibiotics, instead structural modifications of previous classes are often the source 
of new antibiotics.  Antifolates are a colloquial name given to various compound 
classes that are capable of inhibiting the bacterial production of folate or enzymes that 
require folate for proper cellular function.  Dihydrofolate reductase (DHFR) is a crucial 
enzyme in this pathway, and is inhibited in bacteria only by trimethoprim (TMP).  TMP 
is used clinically as a broad-spectrum antibiotic, with activity against Gram-negative 
and Gram-positive pathogens.  TMP resistance, both innate and acquired, has been 
well researched and has attracted many pharmaceutical companies to design the next 
generation antibacterial DHFR drug.  To date, TMP is the only clinically approved 
antibacterial DHFR inhibitor.  
This thesis is a discussion about the culmination of years of research to rationally 
design new DHFR inhibitors, based on a modified TMP-scaffold, for use against TMP-
resistant bacteria.  These charged propargyl-linked antifolates (PLAs) have low 
nanomolar DHFR affinity for both wild-type Staphylococcus aureus DHFR and known  
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resistant DHFR mutants.  They have excellent antibacterial activity against methicillin-
resistant S. aureus (MRSA) and TMP-resistant MRSA clinical isolates with known 
resistance mechanisms.  Charged PLAs also inhibit Mycobacterium tuberculosis (Mtb) 
growth at nanomolar concentrations, as well as multi-drug resistant Mtb and 
extensively-drug resistant Mtb.  A new PLA scaffold was identified with hopes of 
improving antibacterial activity of PLAs against Gram-negative bacteria such as 
Escherichia coli and Klebsiella pneumoniae.  New synthetic methods are reported to 
make PLA generation simpler and more efficient.  PLAs represent promising novel 
antifolates that could be used as antibacterial therapies in the future. 
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1 Antifolates: Mechanism of action, resistance, and recent work 
 
1.1 Folate Biosynthesis 
Rapidly growing cells are in need of a constantly-replenishing supply of a multitude 
of metabolites to ensure survival and replication.  In fact, disrupting metabolite 
biosynthesis has been a proven method of antiproliferative therapy since the late 
1930s.  That decade the sulfonamide drug class was discovered and with it a solution 
to bacterial infections that had plagued humanity throughout time.  Unknown at the 
time of their discovery, the sulfonamides act by interrupting bacterial folate 
biosynthesis, a multi-step enzymatic pathway that utilizes 7,8-dihydrofolate (DHF) to 
generate essential metabolites such as thymidine, methionine, histidine, and purines.  
Since the discovery of sulfonamides, other drug classes, colloquially referred to as 
“antifolates”, that target other essential enzymes along the folate biosynthesis 
pathway have been used as anticancer, antiprotozoal, and antibacterial agents.   
The sulfonamides had an early advantage as antibacterials by targeting an 
enzyme not found in humans, limiting the potential for side effects.  While humans are 
able to acquire DHF from the diet via active transport of its precursor, folic acid (vitamin 
B9), bacteria lack folate transporters and must synthesize DHF in the cell. This has 
limited antifolate use as antibacterials because classical antifolates containing the 
glutamate tail found in natural folate substrates are too highly charged to passively 
diffuse across lipid bilayers.  Classical antifolates have instead found their use in 
anticancer treatments, where they are taken into human cells via folate transporters.
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Figure 1.1 Folate Biosynthetic Pathway and Clinically-Used Antifolates 
  
Bacterial de novo folate biosynthesis is a six-step enzymatic process that converts 
guanosine triphosphate (GTP) to DHF (Figure 1.1). Two enzymatic steps convert 
GTP to 6-hydroxymethyl-7,8-dihydropterin, which is then converted to dihydropteroate 
pyrophosphate via hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK). 
Here, two distinct pathways converge to generate dihydropteroate. Dihydropteroate 
synthase (DHPS) catalyzes the reaction between dihydropteroate pyrophosphate and 
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para-aminobenzoic acid (PABA), a metabolite of the shikimate pathway intermediate 
chorismate.  Dihydrofolate synthase adds a glutamate tail to dihydropteroate to 
generate DHF and complete de novo folate biosynthesis.  From DHF, the bacterial 
and human folate pathways are nearly identical.  Dihydrofolate reductase (DHFR) 
utilizes nicotinamide adenine dinucleotide phosphate (NADPH) as a reducing agent 
to catalyze the conversion of DHF to 5,6,7,8-tetrahydrofolate (THF).  Serine 
hydroxymethyl transferase (SHMT) transfers a methyl group to a pterin-nitrogen and 
the aromatic amine of THF to generate N5,N10-methylene THF (CH2THF).  Here the 
folate biosynthetic pathway diverges, as various enzymes catalyze a one carbon 
transfer to synthesize metabolites essential for normal cell function and replication:  
- Thymidylate synthase (TS) utilizes N5,N10-methylene THF to transfer a methyl 
group to deoxyuridine monophosphate (dUMP), generating deoxythymidine 
monophosphate (dTMP) and recycling DHF.  Without dTMP, cells are unable 
to synthesize RNA and suffer a “thymine-less death.”  
- Methylene tetrahydrofolate reductase (MTHFR) reduces N5,N10-methylene 
THF  to N5-methyl-THF, which is used to generate methionine via remethylation 
of homocysteine by methionine synthase (MTR).  Methionine is required to 
generate S-adenosyl-methionine (SAM), one of the most ubiquitous enzyme 
cofactors, responsible for post translational methylation and essential to proper 
cell function.   
- Methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate 
cyclohydrolase sequentially act to convert N5,N10-methylene THF to N10-formyl 
THF, which is essential for purine biosynthesis and DNA biosynthesis. 
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The folate biosynthetic pathway is fundamental to cell survival and highly conserved 
among all organisms, which has made it an attractive target for drug discovery efforts.  
Herein we will review the history of antifolate drug targets and the current state of their 
clinical relevance. 
 
1.2 DHPS Inhibition – The Sulfonamides 
In the interwar period of the 1920s and 1930s, researchers at Bayer AG 
synthesized a large number of organic dyes to treat bacterial infections.  They believed 
that if the dyes were capable of binding to bacteria they may be also capable of halting 
growth. Gerhard Domagk discovered Prontosil and showed it was effective at reducing 
streptococcal infections in animal models.1,2 Soon after, researchers discovered that 
Prontosil was a prodrug that was cleaved to the active component sulfanilamide,3 a 
known compound synthesized years earlier.  This marked the beginning of the 
sulfonamide (sulfa) drug class of antibiotics, a class that would see a myriad of 
structural modifications to improve upon the drug-like properties of sulfanilamide.  
DHPS, encoded by folP, catalyzes the reaction of DHPP and PABA to generate 
dihydropteroate, the immediate precursor to DHF.  Sulfonamides act as PABA mimics 
by binding in the PABA region of DHPS.   Structurally, sulfa drugs are almost identical 
to pABA, with the aromatic sulfonamide moiety acting as a bioisostere for the benzoic 
acid present in PABA.  The aryl amine moiety of sulfa drugs undergoes the same 
condensation reaction with DHPP, forming a dihydropteroate-like product that cannot 
undergo subsequent DHF synthesis.4,5  A critical reduction in bacterial folate levels 
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follows, leading to thymine depletion and what has been termed a “thymine-less 
death” of the cell.6 
Structurally, sulfonamides are all based on the sulfanilamide scaffold with varying 
substituents on the aryl sulfonamide nitrogen.  These substituents confer greater 
tolerability, increased potency against acquired or innately resistant enzymes, and 
better pharmacokinetic properties.  They also allow for folP mutations to encode 
resistant enzymes with amino acid changes exclusively found where these 
substituents bind without affecting PABA binding.  As we will discuss, this is a common 
resistance mechanism to sulfonamides. 
Historically, sulfanilamide was used to treat streptococcal infections such as 
pneumonia and scarlet fever, and sulfadoxine was used as a combination therapy to 
treat malaria.  Today, sulfonamides are rarely used as mono-therapies.  Sulfadiazine 
is used as a combination therapy with pyrimethamine to treat malaria.  
Sulfamethoxazole is the most widely used sulfa drug as part of a combination therapy 
with trimethoprim (TMP) to treat urinary tract infections caused by Escherichia coli, 
skin and soft tissue infections caused by Staphylococcus aureus, and as prophylaxis 
in HIV/AIDs patients.  
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1.3 Thymidylate Synthase Inhibition 
 
1.3.1 Fluorouracil and its Prodrugs 
In 1954 researchers at Jefferson Medical College observed that hepatoma growth 
in rats was accelerated with the addition of exogenous uracil.7  They also found that 
hepatomas utilized uracil more rapidly than normal cells, indicating that uracil 
metabolism was a crucial difference between cancer cells and healthy cells.  At the 
time, many observations had been made about the profound effect of substituting 
fluorine for hydrogen in biologically relevant molecules, leading to the synthesis of 5-
fluorouracil (5-FU).  Researchers at Hoffmann-LaRoche found that 5-FU inhibited 
tumor growth in rats, paving the way for antimetabolite cancer therapies.8   
Since, 5-FU’s anticancer activity has been explained via two mechanisms: 1) its 
incorporation into RNA which disrupts normal RNA function and processing and 2) 
inhibition of thymidylate synthase (TS) which leads to thymidine depletion in cells.  5-
FUs ability to disrupt normal DNA replication ultimately leads to cell death.  5-FU and 
5-FU pro-drugs, such as flucytosine, capecitabine, and tegafur, have been used as 
anticancer and antifungal therapies.  Herein, our focus will remain on 5-FUs ability to 
inhibit TS as it relates to the folate biosynthetic pathway.9  
5-FU enters cells via the same transport mechanism as uracil10 where it is 
converted to several active metabolites.  Thymidine phosphorylase (TP) catalyzes the 
conversion of 5-FU to fluorodeoxyuridine (FUDR) which is subsequently acted up by 
thymidine kinase (TK) which adds a phosphate and generates fluorodeoxyuridine 
monophosphate (FdUMP).  Normal TS function transfers a methyl group from N5,N10- 
methylene THF (CH2THF) to C-5 of deoxyuridine monophosphate (dUMP), generating 
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deoxythymidine monophosphate (dTMP) to be used for DNA synthesis.  However, 
FdUMP binds to the nucleotide binding site in TS and forms a ternary complex with 
CH2THF, thereby blocking dUMP binding and normal function of TS. 
Capecitabine is a rationally designed, orally available TS inhibitor that is converted 
to 5-FU once it has entered cancer cells and is acted upon by thymidine 
phosphorylase (TP).  A greater tolerance and selectivity can be achieved as many 
cancers see an increase in TP activity relative to healthy cells.  It is currently employed 
in the treatement of colorectal cancers.  Flucytosine, an antifungal drug that is 
converted to 5-FU once taken up into fungal cells, is co-administered with 
amphotericin B as a first-line therapy against cryptococcal meningitis.   
 
1.3.2 Classical Antifolate TS Inhibitors 
More recently, competitive antagonists of CH2THF have begun to see clinical utility 
as alternatives to 5-FU.  Raltitrexed (Tomudex, TDX), first synthesized by ICI 
Pharmaceuticals in 1991,11 was approved for use against colorectal cancers, 
especially in cases where 5-FU is not well tolerated.12  Raltitrexed is considered a 
classical antifolate, characterized by the glutamate tail found in THF.   
Pemetrexed (PMX), a classical antifolate first synthesized by Eli Lilly and Company 
in 1992,13 has been approved for use against pleural mesothelioma and non-small cell 
lung cancers.    PMX is unique among antifolates in that it inhibits multiple enzymes 
along the folate pathway, TS and DHFR.  
While nucleic acid mimics such as 5-FU and classical antifolate CH2THF mimics 
have seen success as cancer therapies, they have not had activity as antibacterials.  
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This is likely due to the highly conserved nature of TS leading to a propensity for 
toxicity via human TS inhibition.  Recently researchers have identified allosteric sites 
capable of TS inhibition, sites that may be less conserved between humans and 
bacterial species.14  Still, thymine depletion remains an attractive and untapped 
method for antibacterial therapies to exploit. 
 
1.4 Flavin-Dependent Thymidylate Synthase 
 
 
 
Until recently, it was believed that the only mechanism by which a cell could 
acquire thymine was de novo biosynthesis via the action of both DHFR and TS 
(encoded by the thyA gene) or via thymidine kinase (tdk) salvage from the extracellular 
environment.  However, genomic studies have revealed that some microorganisms 
lack both thyA and tdk, meaning another process to acquire thymine must exist.15  In 
1989, researchers discovered the thyX gene and identified the protein it encodes, 
flavin-dependent thymidylate synthase (FDTS), and showed it was capable of 
Figure 1.2 Comparison of ThyA TS and ThyX FDTS 
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rescuing thyA deletion in bacteria.15,16  Organisms possessing thyX may be capable 
of rescuing DHFR or TS inhibition.  FDTS has been shown to catalyze the same 
reaction as traditional TS, the methylation of dUMP to dTMP, albeit via a different 
mechanism and using different cofactors.17  TS encoded by thyA uses CH2THF as 
both a one carbon donor and a reducing agent to methylate dUMP, generating dTMP 
and DHF (Figure 1.2).  Recently it has been found that FDTS utilizes reduced FAD 
as a methylene shuttle from CH2THF to dUMP, liberating THF.  Methylene reduction 
is accomplished via FADH-, instead of THF oxidation to DHF.17,18  This can be seen 
in crystal structures of various folates bound to FDTS, with FAD stacked between 
dUMP and the folate binding site, perfectly situated to shuttle the methylene from 
CH2THF to dUMP (Figure 1.3).19  Given the folate products of each enzyme, it is not 
surprising that all organisms that only carry thyA also DHFR to catalyze the reduction 
of DHF to THF, while some organisms carrying thyX have been identified without 
DHFR.  FDTS shares no sequence or structural homology with traditional TS (thyA) 
or DHFR and is found in many pathogenic organism such as Bacillus anthracis, 
Mycobacterium tuberculosis, Helicobacter pylori, and Clostridium difficile, but not in 
humans.  FDTS represents an exciting new drug target and a potential route to use 
thymine depletion mechanisms as antibacterial therapy.   
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Recent efforts to find FDTS small molecule inhibitors have yielded compounds with 
enzyme inhibition activity in the 50-100 nM range; however this research is in its 
infancy although it should provide interesting drug candidates in the future.  Chemical 
structures of recently synthesized FDTS inhibitors are shown in Figure 1.4.20-24 
 
Figure 1.4 Recently Reported ThyX (FDTS) Inhibitors 
 
 
 
Figure 1.3 Crystal Structure of ThyX Bound to Folate (PDB: 4GT9)19 
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1.5 Dihydrofolate Reductase Inhibition  
 
1.5.1 Methotrexate 
DHFR catalyzes the reduction of DHF to THF using NADPH as the reducing co-
factor in prokaryotes and eukaryotes alike.  Antiproliferative therapies targeting DHFR 
were first accomplished with the introduction of the classical antifolate aminopterin in 
1947 to treat various cancers.25  Aminopterin was rationally designed as a competitive 
antagonist of DHF by replacing the pterin ring in DHF with a diaminopteridine ring 
(Figure 1.5).  It was soon replaced with its N-methylated analog methotrexate 
(MTX),26 which is still used today as anticancer therapy and an immunosuppressant 
to treat rheumatoid arthritis.27-29  MTX has not found use as antimicrobial therapy 
despite nanomolar in vitro enzyme activity in various species.  Classical antifolates, 
such as MTX, TDX, and PMX, are highly charged due to their glutamate tail and 
therefore cannot diffuse across lipid bilayers.  This has constrained their use to 
anticancer therapies, where they enter human cells via folate transporters found only 
in higher eukaryotes.  
 
 
 
 
Figure 1.5 Clinically Used DHFR Inhibitors 
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1.5.2 Pyrimethamine/Trimethoprim 
The first non-classical DHFR inhibitors were discovered soon after MTX at 
Wellcome laboratories by George Hitchings.  Instrumental in determining folate 
biosynthesis and function, Hitchings rationally designed the antimalarial DHFR 
inhibitor pyrimethamine.30  Pyrimethamine was synthesized after Hitchings realized 
that Proguanil, an antimalarial treatment at the time,31 was similar in structure to 2,4-
diaminopyrimidines.  Hitchings had previously identified 2,4-diaminopyrimidines 
interrupted folate utilization in Lactobacillus casei.32 
Pyrimethamine is a competitive inhibitor of DHFR due to the similar binding motif 
of 2,4-diaminopyrimidines and the pterin ring of the natural substrate.  Pyrimethamine 
is now co-administered with sulfadioxazine, a member of the sulfa drug class, to 
treat/prevent malarial infections.  Co-administration of DHFR and DHPS inhibitors is 
the preferred strategy for anti-infective therapy. 
Hitchings continued his work on 2,4-diaminopyrimidines, culminating in the 
discovery of trimethoprim (TMP),33 the first antibacterial DHFR inhibitor (Hitchings 
would later receive the Nobel Prize in medicine along with his partner, Gertrude Elion).  
TMP is similar in structure with pyrimethamine, with a methylene joining the 2,4-
diaminopyrimidine ring and the trimethoxybenzene ring. Today, TMP is used in 
combination therapy with sulfamethoxazole (TMP-SMX, Bactrim) for the treatment of 
Gram-positive and Gram-negative infections.  Their wide-spectrum of activity, 
tolerability, resistance rates, and low cost have made TMP and the sulfonamides 
widely used antibiotics.  To date, TMP and the sulfonamides represent the only 
antibacterial antifolates used in a clinical setting. 
13 
 
1.6 Bacterial Resistance to Antifolates 
Bacteria have evolved a myriad of ways to overcome environmental pressures 
including human ingenuity in the form of modern antibiotics.  Despite the large arsenal 
of antibacterial therapies available to clinicians, resistant organisms in clinical settings 
are often difficult to treat.  Whether it be drug-modifying enzymes, membrane 
permeability alterations, extracellular metabolite scavenging, target enzyme 
mutations/upregulation, or horizontal gene transfer, bacterial resistance is an ever-
increasing problem that requires an ever-expanding antibacterial arsenal.  
Resistance to Bactrim began to appear in the 1970s34 shortly after its introduction 
and widespread use clinically.  By the end of the 1980s, reports of E.coli resistance 
rates of 15% and Proteus spp. of 24.9% represented a 7- and 4-fold increase in the 
decade.35,36  In the 1990s, large differences in resistance rates between the developed 
world and the developing world began to appear.  The international WHONET 
surveillance program reported that 62% of E.coli and 53% of K. pneumoniae were 
resistant to TMP-SMX in Latin America, whereas the corresponding rates in the United 
States were only 13% and 23%.37  Simultaneously, an international collection of 
methicillin-resistant S. aureus (MRSA) resistance rates to TMP and SMX were 28% 
and 35% respectively, while S. epidermis resistance rates were 69% for both.38  
Today, resistance rates to E. coli and K. pneumoniae infection is estimated between 
20-30%, while resistance rates to hospital acquired-MRSA infections have been 
reported to be as high as 50%.39  Community-acquired MRSA infections are almost 
completely susceptible to Bactrim, making it a first-line therapy for skin and soft tissue 
infections cause by MRSA.40,41 
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1.6.1 TMP Resistance 
In Gram-positive pathogens, such as staphylococci, TMP resistance has been 
conferred via chromosomal mutations to dfrB, the gene that encodes DHFR.   
Chromosomal mutations have been shown to account for a 256-fold reduction in 
minimum inhibitor concentration (MIC) and accounted for 88% of resistant strains 
tested.42  Of the chromosomal mutations, a single mutation in Phe98 to Tyr98 (F98Y) 
was identified to reduce the enzyme activity of TMP >400 times (IC50 values were 0.01 
vs 4.1 μM against against wild-type (wt) DHFR and F98Y DHFR respectively).42  A 
second mutation was typically seen, either in H30N or H149R, which restored enzyme 
fitness to wild-type levels (Figure 1.6).  The dual mutants, either F98Y/H30N or 
F98Y/H149R, saw 800- to 2400-fold reductions in TMP activity compared to wild-type 
activity.42  Crystal structure analysis of wild-type DHFR revealed two hydrogen bond 
interactions between the carbonyl oxygen of Phe92, the carbonyl of Leu5, and the 
deprotonated 4-amino group of TMP.  In the F98Y DHFR mutant, Phe92 is oriented 
unfavorably for hydrogen bonding with TMP, and simultaneously forms a hydrogen 
bond with Leu5, removing the other hydrogen bond seen in wild-type DHFR.42 
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Figure 1.6 Amino Acid Sequence Alignment of DHFRs.  SaDHFR F98 is highlighted. 
Also the V31I and G43A S1DHFR mutations are highlighted.  
 
 S. aureus TMP resistance conferred via horizontal gene transfer of plasmids was 
first identified as a resistance mechanism in 1984.43,44  Shortly afterwards a dfrA gene 
was discovered encoding a TMP-resistant commonly referred to as S1 DHFR.45  
Believed to originate from S. epidermis, S1 DHFR is 80% homologous to wt DHFR.46  
S1 DHFR is characterized by three point mutations, F98Y, V31I, and G43A, that lead 
to a >1000-fold reduction in TMP activity relative to chromosomal S. aureus DHFR.47  
It is interesting to find the F98Y mutation, discussed earlier as a chromosomal 
mutation, is found in S1 DHFR.  Disruption of TMP diaminopyrimidine binding is a 
fruitful method of resistance.  Crystal structure analysis of S1 DHFR bound to TMP 
revealed a similar hydrogen bonding competition between Tyr98, Leu5, and the 
diaminopyrimidine ring of TMP discussed earlier (Figure 1.7).48  TMP and NADPH 
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binding is also synergistic in wt DHFR, whereas in S1 DHFR Ala43 projects into the 
NADPH binding site resulting in a loss of NADPH enzyme affinity and binding 
synergism with TMP.48  When the Ala43 and Tyr98 residues were incorporated into 
wt S. epidermis, S1 DHFR-comparable resistance levels were observed, indicating 
that binding thermodynamics are the likely culprit of resistance.47   
Figure 1.7 a) TMP Bound to wt SaDHFR (PDB: 3FRE)49 and b) S1DHFR 
(PDB: 2W9S)48 
Recently, plasmids have been discovered carrying new resistance genes encoding 
for TMP-resistant DHFRs.  S3 DHFR, encoded by the dfrG gene, was discovered in 
Thailand in 2005 and showed a 20,000-fold reduction in TMP activity relative to Sa 
DHFR.50  All of the 43 strains analyzed from Thailand were TMP-resistant and 
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contained dfrG, whereas only one of 244 strains from Japan was resistant and 
contained dfrG.  Although its evolutionary origin is unknown, S3 DHFR was 79% 
homologous with TMP-resistant S. haemolyticus DHFR and only 41% homologous 
with TMP-sensitive S. aureus DHFR.  In 2010, genome sequencing identified dfrG in 
a highly-resistant MRSA outbreak in a London hospital.51  In 2014, a study of 598 
MRSA strains from sub-saharan Africa showed that 54% were TMP-resistant.52  Of 
those 324 TMP-resistant strains, 94% were carrying dfrG.  Also, out of 47 MRSA 
strains isolated in European clinics from travelers to Africa, 57% (27 strains) were 
TMP-resistant, and all were carrying dfrG.  Surprisingly, < 1% of TMP-resistant MRSA 
strains carried the F98Y mutation in dfrB.  This would suggest that plasmid-acquisition 
of resistant DHFRs constitutes a larger percentage of clinically relevant TMP-resistant 
MRSA isolates than previously thought.  The molecular mechanism of dfrG resistance 
is still unknown as no S3 DHFR structure has been solved to date.  
In 2009, a new plasmid-acquired DHFR was identified from a porcine MRSA 
isolate, and the gene was named dfrK.53  The presence of dfrK led to a dramatic loss 
in TMP MIC (>256 μg/mL).  Sequence homology between dfrK and dfrG shows 89% 
similarity; however, dfrK shares only 39% and 42% similarity with dfrA and dfrB, 
respectively.  In 2012, two patients were identified in Spain infected with a MRSA 
strain that was shown to be carrying dfrK, indicating the transfer of resistance factors 
from animals to humans.54   
In Gram-negative pathogens, TMP resistance is almost exclusively due to plasmid 
acquisition of genes encoding for a resistant DHFR enzyme.  In 1972, the first report 
of transmissible resistance factors led to an increase in E. coli and Klebsiella 
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aerogenes MIC values to >1 mg/mL.34  This discovery of acquired genes that encode 
for a resistant protein target represented a novel resistance mechanism.55  At the time, 
the study of resistance factors was primarily focused on gene acquisition of drug-
modifying enzymes, namely the beta-lactamases.56  Soon after, a plasmid was found 
in TMP-resistant E. coli that carried a gene encoding for a TMP-sensitive DHFR.57  It 
was shown to confer resistance via a novel mechanism: increasing TMP 
concentrations induced overexpression of the plasmid-acquire gene, thus conferring 
resistance.58  To date, over 30 dfr genes have been identified.  Nomenclature was 
historically confusing, and scientists have since adopted the convention of White and 
Rawlinson.59  There are two distinct DHFR proteins encoded for by dfr genes, type A 
and B.  Plasmid acquired dfrA genes are the most commonly identified TMP-resistant 
genes and code for DHFR proteins similar in size and homology.  They are numbered 
drfAX, where X is an Arabic numeral.  A literature search shows dfrA30 is the latest to 
be identified.60  The B family consists of three genes, dfrB1, dfrB2, dfrB3, that code 
for smaller DHFR proteins.59  Genes of both types are often found on plasmids 
carrying genes that confer resistance to other antibiotics. 
More recently, researchers have tried to identify the prevalence of dfr genes that 
confer resistance.  A 2006 study found that 47% of 350 E. coli strains tested were 
TMP-resistant.  Of those, 66% were carrying an extrachromosomal dfr gene.  Among 
the genes identified, dfrA1 and dfrA17 were found in 45% and 30% of resistant strains 
respectively, although there were marked regional differences.61   A similar study 
found that, out of 320 TMP-resistant E. coli strains, 34% carried dfrA1, 26% carried 
dfrA17, and 16% carried dfrA5.62  The same study also tested TMP-resistant K. 
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pneumoniae strains and found dfrA1 (15%), dfrA5 (13%), dfrA8 (13%), and dfrA12 
(13%) to be most prevalent.  A recent study of Peruvian children found that out of 107 
TMP-resistant clinical isolates 13% were carrying dfrA15 and 10% were carrying 
dfrA1.63  Strains carrying dfrA17 only made up 2% of resistant strains.  Also, 66% of 
isolates did not have a dfr gene that the researchers tested for.  Perhaps the low 
sample size or cohort age affected the results, or perhaps the common TMP-resistant 
mechanism in Peru varies drastically from other areas.  Clearly there is high variability 
of resistance mechanisms due to geography, cohort, and disease state. 
 
1.6.2 Sulfonamide Resistance 
Sulfonamides have been used to treat infections since the 1930s and have seen 
their clinical relevance change over time as resistant organisms have been identified.  
As with TMP-resistance, sulfa-resistance is driven primarily by point mutations in the 
chromosomal gene, folP, or acquisition of sulfa-resistant DHPS from mobile gene 
elements.  Understanding how DHPS catalyzes PABA addition to DHPP can yield 
insight into the molecular mechanisms underpinning DHPS resistance.  Until 2012, 
PABA was believed to nucleophilically displace the pyrophosphate of DHPP via an 
SN2 mechanism.64  However, it was shown to proceed via pyrophosphate 
displacement and carbocation generation in an SN1 fashion.65  The carbocation is 
delocalized through the pterin ring and in Yersinia pestis is stabilized by Asp184 and 
Asp101, which are highly conserved across species.  The incoming aryl amine of 
PABA adds to the carbocation in an SN1 fashion to generate DHP.  Sulfonamides act 
by both competing with PABA and acting as a substrate for DHPS, generating 
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nonfunctional metabolites as a suicide inhibitor.  Mutations are more likely to occur 
outside of the substrate-binding site as binding-site mutations are expected to reduce 
enzyme affinity for the natural substrate.66  Many sulfa drugs have moieties attached 
to aryl sulfonamide functionality that project out of the substrate envelope in close 
proximity to Phe33 and Pro69.  This is the likely reason for known YpDHPS mutations 
in Phe33, Thr67, and Pro69.       
A single point mutation in E. coli DHPS, Phe28Leu, led to a 150-fold loss in 
sulfathiazole DHPS binding, with a 10-fold reduction in enzyme efficiency for PABA 
binding.67  Similarly, a later study found a Phe28Leu mutation conferred resistance in 
E. coli DHPS.68  A Pro64Ser mutation was reported to cause a 100-fold loss in enzyme 
potency of sulfathiazole.69,70 
In S. aureus, the chromosomal mutation explanation of resistance is complicated.  
Nine sulfa-resistant clinical isolates were found to exhibit folP mutations that identified 
at least 14 distinct residues implicated in DHPS resistance.71  No discernable pattern 
was deduced from the placement of the residues, as they appeared to be scattered 
across the DHPS surface.  In S. pneumonieae, sulfa-resistance has been identified 
via nucleotide repeats that lead to amino acid repeats in critical areas of DHPS tertiary 
structure.  One study identified a 6-nucleotide repeat that led to the duplication of Ile66 
and Glu67.72  Deletion of the 6-nucleotide sequence led to a reduction in Km of PABA, 
2.0 to 0.8 μM, and a reduction in Ki of sulfathiazole, 18 to 0.4 μM.  Other studies did 
not confirm the same duplication, but did confirm the existence of other duplicates as 
the cause of sulfa-resistance.73,74  In Staphylococcus pyogenes, resistance has 
existed since sulfanilamide was used in military camps during WWII.75  Sulfa-resistant 
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S. pyogenes folP was shown to exhibit 111 nucleotide point mutations, resulting in a 
30 amino acid difference in DHPS compared to DHPS from susceptible S. pyogenes.76  
Resistant DHPS saw a 137-fold loss in Ki of sulfathiazole and a 3.6-fold loss in Km of 
PABA, indicating a small fitness cost of the mutations.  The authors concluded that 
such a large sequence variability in resistant-DHPS versus susceptible-DHPS must 
be due to a recombination genetic event effecting chromosomal folP. 
Sulfonamide resistance can also be transferred by mobile gene elements carrying 
sul1, sul2, or sul3 that encode for resistant DHPS.77-81  In 2006, out of 350 Bactrim-
resistant E .coli isolates tested, 208 strains were SMX-resistant.  Of those strains, sul1 
was identified in 16%, sul2 in 44%, sul3 in 3%, and sul1 and sul2 in 36.5%.  Seven 
strains out of 208 were SMX-resistant but did not carry one of these plasmid-acquired 
genes.61  A 2016 study of various Gram-negative species, all Bactrim-resistant, 
revealed that 98% of 123 isolates contained at least one plasmid-acquired sul gene.82  
In 44 K. pneumoniae isolates, 21 carried sul1 only, 9 carried sul2, 11 carried both sul1 
and sul2, and 2 carried both sul1 and sul3 genes.  In 43 E. coli isolates, 24 carried 
sul2 and 19 carried both sul1 and sul2 genes.  New therapies targeting DHPS must 
contend with these well-known and well distributed resistance mechanisms. 
While certainly not exhaustive, the resistance mechanisms discussed represent a 
summary of the problems facing any new antifolate antibacterial therapy.  Acquired 
resistance to the often first-line treatment option TMP represents a possible 
dangerous reduction in the available antibiotic arsenal that should motivate future drug 
discovery efforts to design new antifolates to overcome these foreseeable resistance 
mechanisms. 
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1.7 Recent Antibacterial Antifolates 
New antibacterial antifolates should aim to increase the in vitro and in vivo activity 
of DHPS, DHFR, TS, or FDTS inhibitors.  For broad spectrum uses, they should 
improve upon the activity of currently used therapies and improve activity against 
clinically-relevant resistance mechanisms.  For narrow spectrum use they should 
target organisms that are innately resistant to current therapies.  They should also 
display activity against emerging bacterial species resistant to commonly used 
antibiotics such as methicillin, vancomycin, macrolides, and others. 
 
1.7.1 DHPP Mimics  
Researchers have attempted to inhibit DHPS by designing competitive antagonists 
capable of binding to the pterin binding site.  While the PABA binding site is highly 
flexible, the pterin binding site is highly conserved making resistance due to point 
mutations in the active site less likely.  In 1985, Lever et al. reported monocyclic 6-
(alkylamino)-5-nitrosoisocytosines inhibited DHPS at  low micromolar concentrations, 
although no antibacterial acitivity was observed (Figure 1.8).83,84  Crystal structure 
analysis of a single compound revealed conserved pterin-binding interactions.85    It 
has been argued that pterin-based inhibitors are limited due to their highly planar 
structure resulting in poor solubility and lack of scaffold diversity.86  However, the 
highly-conserved nature of the pterin-binding site in DHPS requires pterin-like 
scaffolds.  This has led some to extend pterin-based inhibitors further into the anion-
binding site, thus introducing sp3-hybridized carbons to reduce planarity and perhaps 
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design better inhibitors.  In 2012, Lee  reported novel pyrimido[4,5-c]pyridazine 
derivatives with Bacillus anthracis DHPS inhibition in the low micromolar range that 
introduced extended carboxylic acids to reach the anionic binding site.87  Pterin-sulfa 
conjugates that were designed to act as competitive antagonists of both DHPP and 
PABA showed low micromolar BaDHPS inhibition.88  Crystal structure analysis 
revealed a close similarity to DHPP and PABA binding.  Analogs designed to act as 
transition state mimics, containing a conjugated pterin, sulfa, and phosphate also 
showed promising activity.89  Structural analysis showed three interactions missing 
from the conjugated inhibitor that are present in the natural enzyme substrates.  
Rational drug design could lead to better enzyme binding and better inhibitors. 
 
1.7.2 Iclaprim 
With the success of TMP, many pharmaceutical companies invested in the 2,4-
diaminopyrimidine scaffold to find new antifolate antibacterials with little commercial 
success.  Iclaprim, initially patented by Hoffmann-La Roche in 1997,90 was licensed 
to and developed by Arida AG.   In 2008, after several Phase III trials, the FDA denied 
Arpida approval to market Iclaprim on the basis that it did not demonstrate superiority 
to currently used therapies.  In 2015, the U.S. FDA granted Motif Bio plc fast-track 
Figure 1.8 Examples of Pterin-based DHPS Inhibitors 
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status to intravenous Iclaprim for the treatment of acute bacterial skin and skin 
structure infections.  Iclaprim is currently undergoing Phase III clinical trials. 
Iclaprim’s structure is inspired by TMP, with a 4,5-dihydropyran ring fused to C2 
and C3 of the trimethoxybenzene of TMP.  A cyclopropane extends from C6 of the 
dihydropyran ring (Figure 1.9).  It has demonstrated excellent in vitro activity against 
a broad spectrum of pathogenic bacteria such as MRSA, penicillin-resistant 
pneumococci, TMP-resistant staphylococci and pneumococci, H. influenza and 
Moraxella catarrhalis, C. pneumoniae, and Enterobacteriaceae.91-97  Crystal structure 
analysis of TMP-resistant MRSA carrying the F98Y DHFR mutation revealed that the 
Figure 1.9 a) TMP Bound to S1DHFR Carrying F98Y Mutation (PDB: 
2W9S)48 b) Iclaprim Bound to F98Y DHFR Mutant (PDB: 3FRA)49 
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4-amino moiety on the diaminopyrimidine ring of Iclaprim was able to hydrogen bond 
with Leu5 thus restoring activity (Figure 1.9).  Iclaprim was also shown to have very 
low resistance frequency, calculated to be below 10-10.  Resistance induction 
experiments revealed little change in Iclaprim sensitivity after 15 generations at sub-
optimal concentrations, compared to high level resistance observations for TMP after 
five generations.91 
 
1.7.3 Propargyl-Linked Antifolates 
Although TMP has broad antibacterial activity, organisms such as Pseudomonas 
aeruginosa, Acinetobacter, Neisseria, Brucella, Campylobacter, Actinomycetes, 
mycobacteria, Clostridium spp., and others are still innately resistant to TMP due to a 
resistant DFHR enzyme.  This untapped area of antifolates lends itself to rational 
design of new drugs capable of inhibiting these innately resistant enzymes.  In 2007, 
Anderson and Wright reported the rational design of propargyl-linked antifolates 
(PLAs) with increased enzyme activity against innately TMP-resistant 
Cryptosporidium hominis and Toxoplasma gondii DHFRs.98  In silico modeling of TMP 
and methotrexate in both ChDHFR and TgDHFR revealed a large hydrophobic pocket 
in the PABA ring region of MTX that the trimethoxybenzene ring in TMP was not able 
to fully extend into.99  Multiple TMP-derived compounds were synthesized with various 
carbon-linkers.  An alkyne linker was perfectly suited to extend the trimethoxybenzene 
ring further into the hydrophobic pocket without changing the relative geometry of the 
diaminopyrimidine ring and the trimethoxybenzene ring.  A methyl group was added 
to the C6 position of the diaminopyrimidine ring to maintain hydrophobic contacts lost 
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by the extension of the hydrophobic trimethoxybenzene ring.  Finally, a chiral methyl 
group was added to the propargyl position to increase interactions in the hydrophobic 
pocket.  UCP111A-R (Scheme 1.1) saw a 368-fold increase in ChDHFR affinity 
relative to TMP as measured by IC50 (0.038 μM and 14 μM respectively) and a 5,714-
fold increase in TgDHFR affinity relative to TMP (0.0014 μM and 8 μM respectively).  
Crystal structure analysis revealed that indeed PLAs make favorable interactions with 
the hydrophobic pocket previously unreachable by TMP. 
 
An iterative process of PLA design, biological evaluation, structure determination, 
and next generation PLA design has led to a plethora of PLAs with interesting 
biological activity.  Structure analysis of human DHFR revealed a four residue loop 
(P61, E62, K63, N64, or PEKN) that was absent in ChDHFR.  A second generation of 
biphenyl PLAs was synthesized to exploit this difference by adding a second benzene 
ring projecting from the trimethoxybenzene ring in the first generation PLAs.  
UCP111D-R saw a 38-fold increase in ChDHFR affinity relative to the first generation 
 Scheme 1.1 Evolution of Propargyl-Linked Antifolate (PLA) Scaffold 
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PLAs without an increase in HuDHFR, leading to a 35-fold increase in selectivity of 
ChDHFR over HuDHFR.100  PLAs were tested for antifungal activity in Candida 
glabrata and Candida albicans.101  Second generation PLAs were 13,272 times more 
active against CgDHFR than TMP as measured by IC50 (0.55 nM and 7,300 nM 
respectively) and 2,470 times more active against CaDHFR than TMP.  Second 
generation PLAs also saw good selectivity over HuDHFR in C. glabrata.102   
TMP-resistance in S. aureus is often cause by the F98Y chromosomal mutation 
discussed earlier.  Second generation PLAs saw a 10-fold increase in potency against 
F98Y SaDHFR relative to TMP as measured by IC50 (0.17 μM and 1.70 μM 
respectively).103  A third generation of PLAs introduced heterocyclic functionality to 
move away from the simplified biphenyl PLAs.  While retaining low nanomolar activity 
against SaDHFR, UCP1062 saw a 684-fold increase in S. pyogenes DHFR relative to 
TMP (0.019 μM and 13.0 μM respectively).104  These compounds also saw an 
increase in MIC values relative TMP.  Against MRSA, the best PLA saw a 7-fold 
increase in growth inhibition relative to TMP (0.02 μM and 0.14 μM).  Against S. 
pyogenes, the UCP1062 saw a 48-fold increase (0.012 μM and 0.58 μM). Against 
MRSA clinical isolates the UCP1062 showed 33 times more activity than TMP.104  
Nonracemic PLAs showed excellent activity (111 nM) against F98Y DHFR (TMP - 
3503 nM) and against MRSA isolates carrying the F98Y DHFR mutation showed 
increased activity relative to TMP (0.625 μM versus 10 μM respectively).105 
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1.8 Summary and Closing Remarks 
Antifolates have been staples in the antibiotic arsenal since the discovery of the 
sulfonamides in the 1930s and the non-classical antifolate TMP in the 1960s.  Their 
wide spectrum of activity, relatively low resistance rates, good tolerability, and low cost 
have led to their success.  Both TMP and multiple sulfonamides have been added to 
the WHO’s list of required therapies for developing countries.  However, like all 
antibiotics, ever-growing bacterial resistance threatens their long-term efficacy and 
clinical relevance.  To that end new drugs are required to take up the antifolate mantle 
into the future.  We have discussed the history of, resistance to, and potential next-
generations of antifolates.  All the resources available to modern structure based drug 
design must be employed if we are to be successful and avoid entering the post-
antibiotic era. 
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2 Charged Non-Classical Antifolates with Diverse Antibiotic Activity 
 
2.1 Preface 
 
The following chapter is taken from the following publications: 
- Scocchera, E.,† Reeve, S. M.,† Keshipeddy, S., Lombardo, M. N., Hajian, B., 
Sochia, A. E., Alverson, J. B., Priestley, N. D., Anderson, A. C., Wright, D. L; 
Charged Nonclassical Antifolates with Activity Against Gram-Positive and 
Gram-Negative Pathogens. ACS Med. Chem. Lett. 2016, 7, 692. 
10.1021/acsmedchemlett.6b00120 
†Authors contributed equally 
 
- Reeve, S. M.,† Scocchera, E.,† Ferreira, J. J., G-Dayanandan, N., Keshipeddy, 
S., Wright, D. L., Anderson, A. C; Charged Propargyl-Linked Antifolates Reveal 
Mechanisms of Antifolate Resistance and Inhibit Trimethoprim-Resistant 
MRSA Strains Possessing Clinically Relevant Mutations. J. Med. Chem. 2016, 
59, 6493. 10.1021/acs.jmedchem.6b00688 
†Authors contributed equally 
 
- Hajian, B., Scocchera, E., Keshipeddy, S., G-Dayanandan, N., Shoen, C., 
Kruscinska, J., Reeve, S., Cynamon, M., Anderson, A. C., Wright, D. L; 
Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-
Resistant Mycobacterium tuberculosis. PLoS ONE 2016, 11, e0161740. 
10.1371/journal.pone.0161740 
Contributions:  My contribution to the work was the design of the carboxylate C-rings 
intended to mimic MTX interactions, the synthesis of the propargyl unsubstituted 
inhibitors, and participation in writing the manuscripts.  Stephanie Reeve provided the 
biological data and crystal structure data for Staphylococcus aureus. Michael 
Lombardo provided the biological data for Escherichia coli.  Behnoush Hajian provided 
the IC50 data and crystal structure data for Mycobacterium tuberculosis. Dr. Michael 
Cynamon provided the anti-tuberculosis data.  Santosh Keshipeddy provided the 
asymmetric PLA-COOHs.  
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2.2 Charge Effects on Drug Penetration into Cells 
The natural DHFR substrates, folic acid or dihydrofolate, possess a weakly basic 
pterin ring and a negatively charged glutamate extension that are critical for binding 
of the enzyme. Several crystal structures with different species of DHFR reveal that 
classical antifolates, such as MTX (Fig. 1) and PMX, mimic these motifs of the 
substrate with a basic nitrogenous headgroup that forms strong contacts with an acidic 
residue in the active site and a glutamate tail that forms extensive ionic interactions 
with a basic amino acid (eg. Arg 57 in S. aureus DHFR).1-3 As substrate mimics, 
classical antifolates often possess very high affinity for DHFR. For example, MTX 
inhibits human, Escherichia coli, and Staphylococcus aureus DHFR with Ki values of 
3.4 pM, 1 pM and 1 nM,4,5 respectively.  However, as these classical antifolates carry 
high negative charge at physiological pH, passive diffusion is limited.  Currently, all 
approved anticancer DHFR inhibitors are categorized as classical antifolates as they 
require active transport through human cell membranes to obtain physiologically 
relevant concentrations.     
As bacteria rely on the de novo synthesis of folate cofactors, they do not possess 
folic acid transporters.  Therefore, classical antifolates must enter bacterial cells via 
passive diffusion which is greatly limited due to its highly charged character at 
physiological pH.  Accordingly, the MIC value of the potent enzyme inhibitor MTX 
against wild-type Gram-negative E. coli is over 1 mM.  Even when efflux pumps are 
genetically deleted, the MIC value is 64-256 µM,5 demonstrating that the compound 
has limited permeability and is subject to efflux.  Similarly, against the Gram-positive 
methicillin-resistant S. aureus (MRSA), methotrexate has an MIC50 of 20 µg/mL or 
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MIC90 of 100 µg/mL.7  In contrast, the weakly basic, non-classical antifolate 
trimethoprim (Figure 2.1) with attenuated DHFR inhibition (IC50 values of 23 nM and 
20 nM) is a potent antibacterial against both MRSA and E. coli (MIC values of 0.3125 
µg/mL) and is a first-line agent with sulfamethoxazole against both Gram-negative and 
Gram-positive infections.8-11 
The inclusion of two acidic functional groups in MTX results in a highly 
negatively charged population at physiological pH with a net -2 charge. However, it 
has been appreciated that zwitterionic compounds possessing only a single acidic 
functional group, such as fluoroquinolones (Fig. 1) or tetracyclines, show utility against 
both Gram-positive and Gram-negative bacteria. For example, ciprofloxacin exists 
almost exclusively as the neutral charge-balanced form. The zwitterionic character 
Figure 2.1 A) Antibacterial Agents Effective against Gram-positive or Gram-
negative Bacteria with Relevant Physiological Properties. B) A Previously Reported 
PLA, UCP1021,6 is Compared to a PLA-COOH. 
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contributes to a lower clogD7.4 value (-1.35 for ciprofloxacin), which has been shown 
to correlate with activity in Gram-negative bacteria12.   
 
2.3 PLA Design and Physical Properties 
We have been developing the class of propargyl-linked antifolates (PLAs) as 
inhibitors of DHFR for both Gram-positive and Gram-negative bacteria.  The PLAs, 
like trimethoprim, are characterized as weakly basic non-classical antifolates that 
passively diffuse through membranes and potently inhibit the DHFR enzyme,6,13,14 
often inhibiting the growth of bacterial cells with sub-micromolar MIC values.  We have 
achieved very potent MIC values against MRSA and Streptococcus pyogenes6,13,15 
and good inhibition of Klebsiella pneumoniae14 with compounds similar to UCP1021 
(Figure 2.1).  
We considered a hybrid design that would allow us to capture contacts typically 
made by the negatively charged glutamate tail in folate, while increasing bacterial cell 
permeability. This design would center on replacing the pyridyl function of UCP1021 
with a carboxylic acid. Using Marvin (ChemAxon http://www.chemaxon.com), we 
calculated charges for the molecules in Figure 1 as well as designed PLAs.  At neutral 
pH, the PLAs partition into two primary species: one is deprotonated at the carboxylate 
group with a neutral pyrimidine ring (65%); the other is deprotonated at the carboxylate 
group with a protonated pyrimidine ring, yielding a charge-neutral zwitterionic species 
(35%). The C-ring carboxylic acid functionality (see Figure 2.1 for ring labels) is 
designed to form hydrogen bonds with a conserved basic residue (Arg 57 in SaDHFR 
or EcDHFR) in the active site, respectively. We synthesized eight PLA-COOHs with a 
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C6-ethyl diaminopyrimidine ring, either unsubstituted or methyl-substituted at the 
propargylic position, and a biphenyl system with either 2’ or 3’-methoxy substituents. 
Any inhibitors synthesized with propargylic substitutions were prepared as 
enantiomerically pure compounds. 
 
2.4 Synthesis 
Alternate t-butyl benzoates were coupled via Suzuki reaction to suitable B-ring 
partners to produce biphenyl aldehydes 1a-d. The formyl group was elaborated 
through Wittig homologation and acetylene formation to produce terminal alkynes 2a-
d that were coupled with the diaminopyrimidine headgroup under Sonagashira 
conditions. We were pleased to observe that final deblocking of the t-butyl ester under 
strong acidic conditions proceeded smoothly and in good yield to deliver the 
unbranched inhibitors 3a-d (Scheme 2.1). As initial biological evaluation revealed that 
the para substitution was superior, non-racemic, methyl-branched homologs of 3c and 
3d were prepared using our previously reported method.13  Synthesis of PLA 
enantiomers began from the previously reported chiral thioesters (4-5R/S) that were 
coupled to 4-methylbenzoate boronic acid via Suzuki coupling.  Similar to the earlier 
synthesis, methyl ester cleavage could be achieved as the last synthetic step, 
affording compound 10-11R/S. 
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2.1 Biological Evaluation 
 
All eight compounds were evaluated for their inhibition (IC50 values) of the S. 
aureus (Sa), E. coli (Ec) and human (Hu) DHFR enzymes (Table 1). Structure-activity 
analysis of the placement of the carboxylic acid group showed that, while the ortho 
and meta placement yielded the greatest selectivity over the human enzyme, 
placement in the para position yields the highest affinity to the pathogenic enzymes.  
In SaDHFR, moving the carboxylate from the para position to the meta or ortho 
position results in a 5- and 11-fold loss in activity, respectively.  Activity against 
EcDHFR decreases 6-fold when the carboxylic acid is moved from the para- to meta-
position but only 2.2-fold when moved to the ortho-position. 
Further modifications were made to the para-COOH scaffold including methoxy 
substitution at the R2 position as well as hydrogen and enantiomerically specific 
Scheme 2.1. Synthesis of Unbranched and Asymmetric PLAs. Reagents and Conditions: 
Unbranched Synthesis: (a) Ar-B(OH)2 or Ar-Br, Pd(PPh3)4, Cs2CO3, Dioxane:H2O, 90 °C; (b) methoxymethyl 
triphenylphosphonium chloride, NaOtBu, THF, 0 °C; (c) NaI, TMSCl, MeCN, -20 °C; (d) dimethyl(1-diazo-2-
oxopropyl)phosphonate, K2CO3, MeOH; (e) Iodoethyl diaminopyrimidine, Pd(PPh3)2Cl2, CuI, KOAc, DMF, 50 °C; (f) 
TFA, DCM.  Asymmetric Synthesis: (a) PdCl2(PPh3)2, 4-Methoxycarbonylphenylboronic acid, Dioxane:H2O, 90 
°C; (b) 10% Pd/C, Et3SiH, DCM; (c) Nonaflyl fluoride, P1-t-Bu-tris(tetramethylene) phosphazene base, DMF, -15 °C 
to rt; (d) Iodoethyl diaminopyrimidine, Pd(PPh3)2Cl2, CuI, KOAc, DMF, 50 °C; (e) LiOH, THF:H2O, 32 °C. 
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methyl substitution at the RP position. Moving the methoxy from the R1 (3c) to the R2 
(3d) position resulted in a three-fold increase in SaDHFR activity, from 4.77 nM to 
1.64 nM, respectively. The same change in methoxy position resulted in up to a 5.6-
fold decrease in activity against the EcDHFR enzyme. The placement of the methoxy 
group had little effect on activity against HuDHFR. 
 
Table 1. PLA-COOH Enzyme Inhibition Values with Standard Deviations 
Cmpd RP R1 R2 Ar Sa IC50 (uM) Ec IC50 (uM) Hu IC50 (uM) 
3a H OCH3 H o-COOH     0.359+0.03  0.195+0.008  3.5+0.064 
3b H OCH3 H m-COOH 0.157+0.008 0.526+0.02  1.5+0.056 
3c H OCH3 H p-COOH 0.032+0.01  0.090+0.006  0.817+0.028 
3d H H OCH3 p-COOH 0.011+0.0006 0.507+0.008  0.688+0.039 
10S S-CH3 OCH3 H p-COOH 0.037+0.002  0.177+0.02  0.266+0.015 
10R 
 
R-CH3 OCH3 H p-COOH 0.216+0.02  0.289+0.04  0.52+0.013 
11R R-CH3 H OCH3 p-COOH 0.009+0.0007 0.084 +0.002  0.254+0.015 
11S 
 
S- CH3 H OCH3 p-COOH 0.014+0.001  0.166+0.01 0.502+0.030 
TMP - - - - 0.023+0.003 0.020+0.002 198.2+0.1 
 
 
 
Table 2. PLA-COOH Minimum Inhibitory Concentrations 
Cmpd RP R1 R2 Ar 
S. aureus 
43300 
(µg/mL) 
E. coli 
25922 
(µg/mL) 
E. coli 
NR698 
(µg/mL) 
3a H OCH3 H o-COOH >20 >32 20 
3b H OCH3 H m-COOH 0.625 >20 0.0391 
3c H OCH3 H p-COOH 0.0195 >20 0.0098 
3d H H OCH3 p-COOH 0.0195 >20 0.0049 
10S S-CH3 OCH3 H p-COOH 0.625 >20 0.0391 
10R R-CH3 OCH3 H p-COOH 0.0195 20 0.0012 
11R R-CH3 H OCH3 p-COOH 0.0098 10 0.0024 
11S S- CH3 H OCH3 p-COOH 0.0098 10 0.0024 
TMP - - - - 0.3125 0.3125 0.0098 
MTX - - - - >40 >40 40 
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Previous studies have shown the importance of evaluating enantiomerically pure 
PLAs as the methyl configuration is important, not only for its noncovalent interactions 
but also for directing the binding position of the biaryl system and influencing the 
binding of alternative cofactor anomer.13 A colleague, Dr. Santosh Keshipeddy, 
synthesized propargyl methyl enantiomer of compounds 3c and 3d.  The S-
enantiomer of 3c, inhibitor 10S, exhibits no significant change in IC50 value, unlike the 
R-enantiomer (10R) that has a 7-fold loss in activity. The 3’ methoxy R- and S-
enantiomers, inhibitors 11R and 11S, maintain similar activity as their hydrogen-
substituted counterpart (3d), with Ki values of 1.34, 2.09 and 1.64 nM, respectively. 
 
2.2 Crystal Structure Analysis 
 
Structures of SaDHFR bound to the PLA-COOH compounds 3c and 3d were 
determined by X-ray crystallography in order to validate the design principles.  
SaDHFR bound to 3c shows the coordination of a water molecule between the 
carboxylic acid and the side chain of Arg 57 (Figure 2.2). SaDHFR bound to 3d 
exhibits an extensive water network involving at least four water molecules, 
coordinated between the carboxylic acid of 3d, both amino groups on Arg 57 as well 
as the carbonyl oxygen of Leu 28.  The water network expands to include additional 
hydrogen bonding interactions with the side chains of Asn 56 and Thr 36 (Figure 2.2). 
The binding modes of the inhibitor represent significant differences in the crystal 
structures with inhibitors 3c and 3d. The methoxy substitution in the R1 position of 
compound 3c shifts the biaryl system 1.2 Å toward the solvent exposed surface, which 
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is likely responsible for differences in the observed water networks between 
compounds 3c and 3d (Figure 2.2).   
 
Figure 2.2 Crystal Structures of Inhibitors 3c (PDB ID: 5HF0) and 3d (PDB ID: 5HF2) 
with SaDHFR and NADPH. A) Compound 3c (dark green), a mixture of β–NADPH 
(salmon) and α–NADPH (yellow) and SaDHFR (green). B) Compound 3d (dark 
purple), α-NADPH and SaDHFR (purple). 
 
PLA-COOH inhibitors exhibit high levels of activity against the SaDHFR enzyme 
as well as against S. aureus with the majority of MIC values ranging from 0.0098-
0.625 µg/mL (Table 2). Furthermore, inhibitors 3d, 11R/S were shown to be 
bactericidal with minimum bactericidal concentrations (MBC) less than four times the 
MIC (Table S3).17  The compounds displayed reduced activity against wild-type E. 
coli, with compounds 11R and 11S exhibiting MIC values of 10 µg/mL. Two of the 
major barriers to activity against Gram-negative bacteria are permeability through the 
outer membrane and active removal of the inhibitor via efflux. MIC values were 
measured against NR698,18 an engineered E.coli strain containing an in-frame 
deletion in the imp gene, which encodes a protein essential for outer membrane 
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assembly. This strain, with its compromised outer membrane, is used specifically to 
probe the role of compound permeability in antibacterial action.19 Inhibition 
concentrations against the NR698 strain with compounds 3a-d and 10-11R/S showed 
an approximately 2,000-4,000 fold decrease, indicating that reduced penetration 
through the outer membrane is limiting PLA activity in E. coli. Efflux activity is unlikely 
as MIC values were not shifted in ΔacrB, ΔmacB, ΔemrB, or ΔacrF strains (MIC values 
ΔacrB strain are shown in Supplemental Table S4, other data not shown). Similarly, 
MIC values were maintained between wild-type and porin knockout strains (ΔompF 
and ΔompC), validating that the compounds passively diffuse into the cells rather than 
gaining access through porins. MIC values for MTX for these strains were measured 
as >40 µg/mL (Table 2). 
The extraordinary activity in the Gram-positive bacteria indicates that the design 
principles were successful, allowing the incorporation of negatively charged 
functionality to create key contacts with the enzyme without compromising cellular 
penetration, as with MTX. Alternatively in Gram-negative bacteria, the highly negative 
lipopolysaccharide barrier may mitigate the penetration of the negatively charged 
population of PLAs by electrostatic repulsion.  This work motivates a further analysis 
of key physicochemical properties as outlined in Figure 2.1 to potentially reduce the 
population of negatively charged species to favor charge-neutral zwitterions and 
enhance Gram-negative penetration.  
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2.3 Toxicity and Pharmacokinetic Properties 
 
To examine the drug-like potential of the PLA-COOHs, a series of in vitro assays 
probed their effects on human cells, their inhibition of critical CYP isoforms and their 
lifetime in microsomal stability assays. The PLA-COOHs had no measurable 
cytotoxicity toward mammalian cells at concentrations of at least 100 µM. For 
example, compound 3c had an IC50 value greater than 500 µM toward HepG2, MCF-
10A and human dermal fibroblast cells. Coupling the potent activity against Gram-
positive bacterial cells with low cytotoxicity yields a high therapeutic index (>500,000). 
We have also been following cytochrome P450 inhibition for the PLA series and 
therefore measured the activity of compound 3c against CYP3A4 and CYP2D6, two 
of the most prevalent isoforms. Inhibition of both enzymes required concentrations 
greater than 50 µM, indicating the compound may not interfere with the metabolism of 
other drugs. Finally, we tested the lifetime of compound 3c in microsomal stability 
assays. Compound half-life was measured by following the parent compound using 
UPLC. The phase I half-life was 99 min and for phase II was approximately 87 min.  
The results of these in vitro experiments point toward an excellent drug-like profile for 
the PLA-COOHs.  
2.4 PLA-COOH Activity against Mycobacterium tuberculosis 
 
Tuberculosis (TB) is responsible for one million deaths every year and is one of 
the top deadly infections worldwide.20  It is caused by Mycobacterium tuberculosis 
(Mtb), an acid-fast bacteria with an impermeable cell wall.  Mtb is able to lie dormant 
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in macrophages for years in its latent form before multiplying, often in immune-
compromised patients such as HIV patients.21  The current treatment regimen is a 
combination therapy of four medications, isoniazid, rifampicin, ethambutol, and 
pyrazinamide, for two months followed by four months of isoniazid and rifampicin 
treatment.  This regimen is often incompatible with HIV and diabetes medications, 
making treatment difficult.  Also, the emergence of multi drug-resistant (MDR) TB and 
extensively drug-resistant (XDR) TB has limited treatment options further. MDR-TB 
strains are resistant to isoniazid and rifampicin.  Current treatment consists of eight to 
ten drugs administered over one to two years.  XDR-TB strains, in addition to isoniazid 
and rifampicin resistance, are also resistant to fluoroquinolones and one of the 
second-line injectables, amikacin, kanamycin, and capreomycin.  New therapies, 
capable of shortening treatment duration, capable of targeting MDR- and XDR-TB, 
and compatible with other commonly concurrently administered drugs are urgently 
needed.20,22-27 
Antifolates are not a currently exploited drug target in TB therapy.  Clinically used 
antifolates, methotrexate, pyrimethamine, and trimetrexate (TMX), are potent 
inhibitors of Mtb DHFR but have little anti-TB activity, likely due to the inability to 
permeate the Mtb cell wall.  One of the inspirations for synthesizing the COOH-PLAs 
was the zwitterionic character of the compound aiding in penetration through Gram-
negative bacteria. Despite the failure of our rationale, we tested these compounds 
against Mtb in the hope of penetrating a much different cell wall.   
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Table 3. PLA-COOH MtbDHFR Activity and Anti-TB Activity against MDR-TB and 
XDR-TB Strains 
 IC50 (nM)                  MIC (μg/mL) 
Cmpd MtbDHFR HuDHFR 
Mtb 
Erdman 
Mtb 
5 
Mtb 
365 
Mtb 
276 
Mtb 
352 
Mtb 
56 
Mtb 
C-31 
3c 173 ± 15 870 ± 33 4 8 4 16 16 16 >32 
3b 311 ± 24 1577 ± 61 1 ND ND ND ND ND ND 
10R 111 ± 7 1955 ± 46  0.5 ND ND ND ND ND ND 
11R 177 ± 25 1015 ± 60  <0.03 0.25 <0.03 ND 0.06 0.06 8 
3d 460 ± 50 688 ± 40 0.125 2 0.125 ND 0.5 0.5 8 
TMX 17  ND 4 ND ND ND ND ND ND 
TMP 19,560 ± 200 97,179 ± 500 256 ND ND ND ND ND ND 
INH - - 0.03 4 2 ND 1 1 4 
TMX – Trimetrexate; TMP – Trimethoprim; INH – Isoniazid  
We were delighted that PLA-COOHs exhibited good anti-mycobaterium activity 
(Table 2).  The best compound 11R was <0.03 μg/mL, more active in fact than 
isoniazid, a clinically-used TB drug.  Enzyme activity revealed good nanomolar 
inhibition, with 10R being the best MtbDHFR inhibitor at 111 nM.  However 
trimetrexate was nearly 10-fold more active against MtbDHFR with an IC50 of 17 nM, 
despite its MIC value of 4 μg/mL.  We believe this discrepancy can be explained by 
our COOH-PLAs being better able to permeate the Mtb cell. 
We tested our COOH-PLAs against various clinically isolated MDR- and XDR-TB 
strains (in Table X, MDR strains are Mtb 365, Mtb 276, MTb 352, Mtb 56 and Mtb C-
31; the single XDR strain is Mtb 5).    The best compound 11R showed excellent 
activity against three of the MDR-TB strains tested, with an MIC value no higher than 
0.06 μg/mL.  Against XDR-TB 11R saw a 16-fold increase in activity compared to 
isoniazid, 0.25 μg/mL vs. 4 μg/mL respectively.   
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Figure 2.3 Crystal Structure of 3c Bound to MtbDHFR. (PDB: 5JA3) 
In order to investigate the molecular interactions between MtbDHFR and the PLA-
COOHs, MtbDHFR was crystallized with 3c, an earlier PLA with promising Mtb 
activity, albeit less than 11R.  Structure analysis revealed that the 2,4-
diaminopyrimidine ring makes the expected hydrogen bonds with Asp27, the 
carbonyls of I5 and I94, and a water-mediated hydrogen bond with the carbonyl of 
Glu111 and Thr113 (Figure 2.3).  MtbDHFR carries a Tyr100 in a similar position of 
the TMP-resistant F98Y S. aureus mutant; however, it does not appear to disrupt 
hydrogen bonding.  Phe31 appears to make pi-stacking interactions with the 
diaminopyrimidine and alkyne.  The C-ring acid in 3c makes a hydrogen bond with 
Arg60; however, it is not an idealized interaction between carboxylic acid and Arg60 
because the rigid PLA structure doesn’t allow for proper orientation.   
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2.5 Conclusion 
In summary, this work presents a new series of hybrid antifolates that 
demonstrates how the incorporation of a carboxylate moiety to mimic one of the key 
interactions common to classical antifolates can be incorporated into the propargyl-
linked antifolate architecture without compromising the ability to gain access to the 
target enzyme, DHFR. The evaluation of eight inhibitors showed that they have high 
enzyme affinity and increased antibacterial activity against MRSA, E. coli, and M. 
tuberculosis relative to earlier PLAs. High resolution crystal structures of two 
compounds with S. aureus DHFR reveal that affinity is enhanced by water-mediated 
contacts between the carboxylate and Arg 57 in the active site. Against M. tuberculosis 
DHFR, high resolution crystal structure analysis reveals a non-idealized interaction 
between the C-ring carboxylate and Arg 60.  Additional profiling supports the 
development of these compounds as antibacterial candidates. 
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2.6 Experimental  
 
All reactions, unless specified, were conducted under an atmosphere of argon in 
glassware that had been flame dried. Methylene chloride (CH2Cl2) was used from 
Baker Cycle-Tainers, anhydrous toluene, tert-butyl methyl ether (MTBE), dioxane, 
triethylamine and dimethylformamide (DMF) were purchased from Sigma-Aldrich. 
Josiphos was purchased from STREM, pyridine boronic acid from Frontier Scientific, 
MeMgBr (3.0 M in diethyl ether); CuBrSMe2 from Sigma-Aldrich and was 
recrystallized from Me2S prior to use. Where appropriate, control of temperature was 
achieved with a Neslab Cryocool CC-100 II immersion cooler, ice-bath or a heated oil 
bath. 1H NMR spectra were recorded at 400 MHz, and/or at 500 MHz and calibrated 
to the CDCl3 peak at 7.28 ppm. 13C NMR spectra were recorded at 100MHz, and/or 
at 125 MHz and calibrated to the CDCl3 peak at 77.23 ppm. Chemical shifts are 
reported in units of parts per million (ppm). High-resolution mass spectra were 
obtained on the JMS-AX505HA instruments and/or on an AccuTOF instrument at the 
University of Connecticut. Flash chromatography was performed on Silica Gel, 40 
microns, 32-63 flash silica and/or -NH2 capped spherical silica gel. Thin layer 
chromatography was performed on silica gel (Silica Gel 60 F254) glass plates and the 
compounds were visualized by UV and/or potassium permanganate stain.  
 
 
55 
 
 
3’-Formyl-4’-methoxybiphenyl-2-carboxylic acid tert-butyl ester (1a). In a screw 
cap pressure vessel fitted with a stir bar was added 2-(tert-butoxycarbonylphenyl) 
boronic acid (1.00 g, 4.98 mmol), 3-bromo-5-methoxybenzaldehyde (1.28 g, 4.98 
mmol), Pd(PPh3)4 (0.29 g, 0.25 mmol, 5% Pd), Cs2CO3 (4.09 g, 12.45 mmol), 
anhydrous dioxane (20 mL), and water (2 mL). The mixture was degassed by bubbling 
argon through for 15 min, sealed, and heated to 100 °C for 4 h, when TLC showed 
consumption of aryl bromide.  The reaction was diluted with saturated brine and 
extracted 3x with EtOAc.  The combined organic layers were dried over NaSO4 and 
filtered. The filtrate was concentrated and purified by flash column chromatography 
(SiO2, 40 g, 5% EtOAc/hexanes) to afford bicyclic ester 1a as a slightly yellow solid 
(1.34 g, 86%); 1H NMR (500 MHz, CDCl3) δ 10.55 (s, 1H), 7.86 (d, J = 2.4 Hz, 1H), 
7.84 (dd, J = 7.7, 1.4 Hz, 1H), 7.57 (dd, J = 8.5, 2.4 Hz, 1H), 7.53 (td, J = 7.6, 1.5 Hz, 
1H), 7.44 (td, J = 7.6, 1.3 Hz, 1H), 7.35 (dd, J = 7.7, 1.3 Hz, 1H), 7.08 (d, J = 8.5 Hz, 
1H), 4.03 (s, 3H), 1.38 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 189.5, 167.6, 161.1, 
140.5, 136.0, 134.5, 132.7, 130.9, 130.6, 129.9, 128.7, 127.3, 124.4, 111.4, 81.5, 
55.9, 27.8; HRMS (DART [M+H]+) m/z 313.1433 (calculated for C19H21O4, 313.1440). 
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3’-Formyl-4’-methoxybiphenyl-3-carboxylic acid tert-butyl ester (1b). According 
to the general Suzuki coupling procedure, 3-(tert-butoxycarbonylphenyl) boronic acid 
(0.50 g, 2.25 mmol), 3-bromo-5-methoxybenzaldehyde (0.48 g, 2.25 mmol), 
Pd(PPh3)4 (0.13 g, 0.11 mmol, 5% Pd), Cs2CO3 (1.47 g, 4.5 mmol), anhydrous dioxane 
(10 mL), and water (1 mL) were added to a 50 mL screw cap pressure vessel.  The 
mixture was degassed by bubbling argon through for 15 min, sealed, and heated to 
100 °C for 4 h, when TLC showed consumption of aryl bromide. The reaction was 
diluted with saturated brine and extracted 3x with EtOAc.  The combined organic 
layers were dried over NaSO4 and filtered. The filtrate was concentrated and purified 
by flash column chromatography (SiO2, 20 g, 5% EtOAc/hexanes) to afford bicyclic 
ester 1b as a slightly yellow solid (0.52 g, 74%); 1H NMR (500 MHz, CDCl3) δ 10.57 
(s, 1H), 8.23 (t, J = 1.9 Hz, 1H), 8.14 (d, J = 2.5 Hz, 1H), 8.00 (dt, J = 7.7, 1.4 Hz, 1H), 
7.87 (dd, J = 8.6, 2.5 Hz, 1H), 7.77 (dt, J = 7.7, 1.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 
7.14 (d, J = 8.6 Hz, 1H), 4.03 (s, 3H), 1.67 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
189.7, 165.7, 161.5, 139.7, 134.4, 133.0, 132.7, 130.7, 128.8, 128.3, 127.6, 127.0, 
125.0, 112.3, 112.3, 81.3, 55.9, 28.2, 28.2; HRMS (DART [M+H]+) m/z 313.1434 
(calculated for C19H21O4, 313.1440). 
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3’-Formyl-4’-methoxybiphenyl-4-carboxylic acid tert-butyl ester (1c). According 
to the general Suzuki coupling procedure, 4-(tert-butoxycarbonylphenyl) boronic acid 
(1.00 g, 4.98 mmol), 3-bromo-5-methoxybenzaldehyde (1.28 g, 4.98 mmol), 
Pd(PPh3)4 (0.29 g, 0.25 mmol, 5% Pd), Cs2CO3 (4.09 g, 12.45 mmol), anhydrous 
dioxane (20 mL), and water (2 mL) were added to a 50 mL screw cap pressure vessel.  
The mixture was degassed by bubbling argon through for 15 min, sealed, and heated 
to 100 °C for 4 h, when TLC showed consumption of aryl bromide. The reaction was 
diluted with saturated brine and extracted 3x with EtOAc.  The combined organic 
layers were dried over NaSO4 and filtered. The filtrate was concentrated and purified 
by flash column chromatography (SiO2, 40 g, 5% EtOAc/hexanes) to afford bicyclic 
ester 1c as a slightly yellow solid (1.23 g, 79%); 1H NMR (500 MHz, CDCl3) δ 10.53 
(s, 1H), 8.12 (d, J = 1.9 Hz, 1H), 8.06 (d, J = 8.1 Hz, 2H), 7.83 (d, J = 10.5 Hz, 1H), 
7.63 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 8.7 Hz, 1H), 4.00 (s, 3H), 1.63 (s, 9H); 13C NMR 
(126 MHz, CDCl3) δ 189.5, 165.5, 161.7, 143.3, 134.4, 132.7, 130.8, 130.0, 126.9, 
126.3, 125.0, 112.3, 81.1, 55.9, 28.2; HRMS (DART [M+H]+) m/z 313.1412 (calculated 
for C19H21O4, 313.1440).  
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5’-Formyl-3’-methoxybiphenyl-4-carboxylic acid tert-butyl ester (1d). According 
to the general Suzuki coupling procedure, 4-(tert-butoxycarbonylphenyl) boronic acid 
(0.50 g, 2.25 mmol), 3-bromo-4-methoxybenzaldehyde (0.48 g, 2.25 mmol), 
Pd(PPh3)4 (0.13 g, 0. 11 mmol, 5% Pd), Cs2CO3 (1.47 g, 4.5 mmol), anhydrous 
dioxane (10 mL), and water (1 mL) were added to a 50 mL screw cap pressure vessel.  
The mixture was degassed by bubbling argon through for 15 min, sealed, and heated 
to 100 °C for 4 h, when TLC showed consumption of aryl bromide. The reaction was 
diluted with saturated brine and extracted 3x with EtOAc.  The combined organic 
layers were dried over NaSO4 and filtered. The filtrate was concentrated and purified 
by flash column chromatography (SiO2, 20 g, 5% EtOAc/hexanes) to afford bicyclic 
ester 1d as a slightly yellow solid (0.54 g, 77%); 1H NMR (500 MHz, CDCl3) δ 10.09 
(s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.74 (m, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 
1.7 Hz, 2H), 3.97 (s, 3H), 1.66 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 191.9, 165.4, 
160.7, 143.4, 142.5, 138.4, 131.7, 130.1, 126.9, 122.3, 120.2, 111.7, 81.3, 55.8, 55.7, 
28.2; HRMS (DART [M+H]+) m/z 313.1450 (calculated for C19H21O4, 313.1440). 
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4’-Methoxy-3’-prop-2-ynylbiphenyl-2-carboxylic acid tert-butyl ester (2a). In a 
dried RB flask fitted with a stir bar under argon atmosphere, methoxymethyl 
triphenylphosphonium chloride (1.37 g, 4.0 mmol) was dissolved in dry THF (10 mL) 
and cooled to 0 °C.  Sodium tert-butoxide (0.39 g, 4.0 mmol) was added (reaction 
turned dark red) and stirred for 20 min.  Aldehyde 1a (0.50 g, 1.6 mmol) was added in 
dry THF (5 mL, reaction turned orange).  TLC analysis showed consumption of 1a 
after 30 min. The reaction was quenched with saturated NH4Cl and extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
NaSO4, and filtered.  The filtrate was passed through a column of silica gel (10% 
EtOAc in hexanes) to afford a mixture of enol ether isomers, which were immediately 
hydrolyzed in the subsequent step. 
In a dried RB flask fitted with a stir bar under argon atmosphere was added enol ether 
(0.48 g, 1.41 mmol) in MeCN (20 mL).  Sodium iodide (0.23 g, 1.55 mmol) was added 
and the reaction mixture was cooled to -20 °C.  TMSCl (0.17 g, 1.55 mmol) was added 
and stirred at -20 °C for 30 min, when TLC showed SM consumption.  The reaction 
was diluted with EtOAc (20 mL) and Na2S2O3 (10 mL) and stirred as reaction warmed 
to rt.  The organic layer was separated and the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over 
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NaSO4, and filtered. The filtrate was concentrated and used without further 
purification.  
In a dried RB flask fitted with a stir bar under argon atmosphere was added aldehyde 
(0.28 g, 0.86 mmol) in MeOH (5 mL).  The Ohira-Bestmann reagent (0.33 g, 1.72 
mmol) was added (turned yellow/green) and cooled to 0 °C. Powdered K2CO3 (0.36 
g, 2.58 mmol) was added and stirred at 0 °C for 2 h, when TLC showed consumption 
of SM. The reaction was diluted with brine (5 mL) and extracted with EtOAc (3 x 15 
mL). The combined organic layers were washed with brine, dried over NaSO4 and 
filtered. The filtrate was concentrated and purified by flash column chromatography 
(SiO2, 10 g, 5% EtOAc/hexanes) to afford bicyclic alkyne 2a as a white solid (0.20 g, 
39% yield 3 steps); 1H NMR (500 MHz,CDCl3) δ 7.81 (dd, J = 7.7, 1.4 Hz, 1H), 7.54 
(dd, J = 2.4, 1.2 Hz, 1H), 7.52 (td, J = 7.5, 1.3, 1H), 7.42 (td, J = 7.5, 1.3 Hz, 1H), 7.38 
(dd, J = 7.5, 1.3 Hz, 1H), 7.25 (dd, J = 8.3, 2.3 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 3.93 
(s, 3H), 3.66 (d, J = 2.7 Hz, 2H), 2.19 (t, J = 2.7 Hz, 1H), 1.37 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 168.2, 156.2, 141.8, 134.2, 133.1, 130.7, 130.6, 129.6, 129.3, 129.3, 
127.9, 126.8, 124.0, 109.7, 81.7, 81.2, 70.7, 55.6, 55.6, 27.8, 19.3. HRMS (DART 
[M]+) m/z 322.1573 (calculated for C21H23O3 322.1569). 
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4’-Methoxy-3’-prop-2-ynylbiphenyl-3-carboxylic acid tert-butyl ester (2b). In a 
dried RB flask fitted with a stir bar under argon atmosphere, methoxymethyl 
triphenylphosphonium chloride (0.88 g, 2.56 mmol) was dissolved in dry THF (8 mL) 
and cooled to 0 °C.  Sodium tert-butoxide (0.25 g, 2.56 mmol) was added (reaction 
turned dark red) and stirred for 20 min.  Aldehyde 1b (0.40 g, 1.28 mmol) was added 
in dry THF (4 mL, reaction turned orange).  TLC analysis showed consumption of 1b 
after 30 min. The reaction was quenched with saturated NH4Cl and extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
NaSO4 and filtered.  The filtrate was passed through a column of silica gel (10% EtOAc 
in hexanes) to afford a mixture of enol ether isomers, which were immediately 
hydrolyzed in the subsequent step. 
In a dried RB flask fitted with a stir bar under argon atmosphere was added enol ether 
(0.39 g, 1.15 mmol) in MeCN (15 mL).  Sodium iodide (0.21 g, 1.38 mmol) was added 
and the reaction mixture was cooled to -20 °C.  TMSCl (0.15 g, 1.38 mmol) was added, 
stirred at -20 °C for 30 min, when TLC showed SM consumption.  The reaction was 
diluted with EtOAc (20 mL) and Na2S2O3 (10 mL) and stirred as reaction warmed to rt.  
The organic layer was separated and the aqueous phase was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine, dried over NaSO4 
and filtered. The filtrate was concentrated and used without further purification.  
In a dried RB flask fitted with a stir bar under argon atmosphere was added aldehyde 
(0.30 g, 0.92 mmol) in MeOH (5 mL).  The Ohira-Bestmann reagent (0.35 g, 1.84 
mmol) was added (turned yellow/green) and cooled to 0 °C. Powdered K2CO3 (0.38 
g, 2.76 mmol) was added and stirred at 0 °C for 2 h, when TLC showed consumption 
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of SM. The reaction was diluted with brine (5 mL) and extracted with EtOAc (3 x 15 
mL). The combined organic layers were washed with brine, dried over NaSO4 and 
filtered. The filtrate was concentrated and purified by flash column chromatography 
(SiO2, 10 g, 5% EtOAc/hexanes) to afford bicyclic alkyne 2b as a white solid (0.13 g, 
31% yield 3 steps); 1H NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 
7.82 (d, J = 2.2 Hz, 1H), 7.79 – 7.74 (m, 1H), 7.53 (dd, J = 8.4, 2.2 Hz, 1H), 7.50 (t, J 
= 7.7 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 3.91 (s, 3H), 3.67 (d, J = 2.6 Hz, 2H), 2.24 (t, 
J = 2.6 Hz, 1H), 1.66 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 165.9, 156.6, 140.9, 132.7, 
132.5, 130.7, 130.7, 130.7, 128.6, 127.8, 127.7, 127.7, 127.6, 127.6, 126.6, 125.0, 
110.4, 81.8, 81.1, 70.7, 55.6, 28.2, 19.3;  HRMS (DART [M]+) m/z 322.1578 
(calculated for C21H23O3 322.1569). 
 
4’-Methoxy-3’-prop-2-ynylbiphenyl-4-carboxylic acid tert-butyl ester (2c). In a 
dried RB flask fitted with a stir bar under argon atmosphere, methoxymethyl 
triphenylphosphonium chloride (1.37 g, 4.0 mmol) was dissolved in dry THF (10 mL) 
and cooled to 0 °C.  Sodium tert-butoxide (0.39 g, 4.0 mmol) was added (reaction 
turned dark red) and stirred for 20 min.  Aldehyde 1c (0.50 g, 1.6 mmol) was added in 
dry THF (5 mL, reaction turned orange).  TLC analysis showed consumption of 1c 
after 30 min. The reaction was quenched with saturated NH4Cl and extracted with 
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EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
NaSO4 and filtered.  The filtrate was passed through a column of silica gel (10% EtOAc 
in hexanes) to afford a mixture of enol ether isomers, which were immediately 
hydrolyzed in the subsequent step. 
In a dried RB flask fitted with a stir bar under argon atmosphere was added enol ether 
(0.50 g, 1.47 mmol) in MeCN (20 mL).  Sodium iodide (0.26 g, 1.76 mmol) was added 
and the reaction mixture was cooled to -20 °C.  TMSCl (0.19 g, 1.76 mmol) was added, 
stirred at -20 °C for 30 min, when TLC showed SM consumption.  The reaction was 
diluted with EtOAc (20 mL) and Na2S2O3 (10 mL and stirred as the reaction warmed 
to rt.  The organic layer was separated and the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over 
NaSO4 and filtered. The filtrate was concentrated and used without further purification.  
In a dried RB flask fitted with a stir bar under argon atmosphere was added aldehyde 
(0.34 g, 1.03 mmol) in MeOH (7 mL).  The Ohira-Bestmann reagent (0.40 g, 2.06 
mmol) was added (turned yellow/green) and cooled to 0 °C. Powdered K2CO3 (0.43 
g, 3.09 mmol) was added and stirred at 0 °C for 2 h, when TLC showed consumption 
of SM. The reaction was diluted with brine (5 mL) and extracted with EtOAc (3 x 15 
mL). The combined organic layers were washed with brine, dried over NaSO4 and 
filtered. The filtrate was concentrated and purified by flash column chromatography 
(SiO2, 12 g, 5% EtOAc/hexanes) to afford bicyclic alkyne 2c as a white solid (0.23 g, 
45% yield 3 steps); 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 8.2 Hz, 2H), 7.85 (d, 1H), 
7.66 (d, J = 8.2 Hz, 2H), 7.52 (dd, J = 8.6, 2.4 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 3.89 
(s, 3H), 3.67 (d, J = 2.7 Hz, 2H), 2.27 (t, J = 2.5 Hz, 1H), 1.66 (s, 9H); 13C NMR (126 
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MHz, CDCl3) δ 165.8, 156.9, 156.9, 144.8, 132.4, 130.2, 129.9, 129.9, 127.8, 126.7, 
126.4, 125.0, 125.0, 110.4, 81.7, 77.4, 77.1, 76.9, 70.9, 55.5, 28.3, 19.4;  HRMS 
(DART [M]+) m/z 322.1539 (calculated for C21H23O3 322.1569). 
 
3’-Methoxy-5’-prop-2-ynylbiphenyl-4-carboxylic acid tert-butyl ester (2d). In a 
dried RB flask fitted with a stir bar under argon atmosphere, methoxymethyl 
triphenylphosphonium chloride (1.76 g, 5.12 mmol) was dissolved in dry THF (12 mL) 
and cooled to 0 °C.  Sodium tert-butoxide (0.49 g, 5.12 mmol) was added (reaction 
turned dark red) and stirred for 20 min.  Aldehyde 1d (0.64 g, 2.05 mmol) was added 
in dry THF (7 mL, reaction turned orange).  TLC analysis showed consumption of 1d 
after 30 min. The reaction was quenched with saturated NH4Cl and extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
NaSO4 and filtered.  The filtrate was passed through a column of silica gel (10% EtOAc 
in hexanes) to afford a mixture of enol ether isomers, which were immediately 
hydrolyzed in the subsequent step. 
In a dried RB flask fitted with a stir bar under argon atmosphere was added enol ether 
(0.56 g, 1.64 mmol) in MeCN (20 mL).  Sodium iodide (0.27 g, 1.8 mmol) was added 
and the reaction mixture was cooled to -20 °C.  TMSCl (0.20 g, 1.8 mmol) was added, 
stirred at -20 °C for 30 min, when TLC showed SM consumption.  The reaction was 
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diluted with EtOAc (20 mL) and Na2S2O3 (10 mL), and stirred as reaction warmed to 
rt.  The organic layer was separated and the aqueous phase was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine, dried over NaSO4 
and filtered. The filtrate was concentrated and used without further purification.  
In a dried RB flask fitted with a stir bar under argon atmosphere was added aldehyde 
(0.38 g, 1.15 mmol) in MeOH (7 mL).  The Ohira-Bestmann reagent (0.44 g, 2.3 mmol) 
was added (turned yellow/green) and cooled to 0 °C. Powdered K2CO3 (0.48 g, 3.45 
mmol) was added and stirred at 0 °C for 2 h, when TLC showed consumption of SM. 
The reaction was diluted with brine (5 mL) and extracted with EtOAc (3 x 15 mL). The 
combined organic layers were washed with brine, dried over NaSO4 and filtered. The 
filtrate was concentrated and purified by flash column chromatography (SiO2, 12 g, 
5% EtOAc/hexanes) to afford bicyclic alkyne 2d as a white solid (0.22 g, 34% yield 3 
steps); 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.5 Hz, 2H), 
7.23 (s, 1H), 7.07 (s, 1H), 7.00 (s, 1H), 3.92 (s, 3H), 3.71 (d, J = 2.6 Hz, 2H), 2.27 (t, 
J = 2.7 Hz, 1H), 1.66 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 165.7, 160.3, 144.9, 141.9, 
138.3, 131.1, 129.9, 127.0, 119.4, 113.1, 111.6, 81.6, 81.1, 70.9, 55.5, 28.3, 25.0. 
HRMS (DART [M]+) m/z 322.1572 (calculated for C21H23O3 322.1569).      
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6-Ethyl-5-[3-(2-methoxy-5-(2-carboxyphenyl)-phenyl)-prop-1-ynyl]-pyrimidine-
2,4-diamine (3a). In a screw cap vial fitted with a stir bar and a septum, was added 
alkyne (0.10 g, 0.31 mmol), iodo-ethylpyrimidine (0.06 mg, 0.24 mmol), Pd(PPh3)2Cl2 
previously doped with 10% CuI by weight (0.01 g, 0.02 mmol), and KOAc (0.23 g, 2.38 
mmol). DMF (3 mL) was added and argon was bubbled through the stirring solution 
for 10 min. The vial was sealed and heated to 50 °C until the reaction was complete 
by TLC (2-3 h).  The reaction was dried in vacuo using toluene as an azeotrope.  The 
residue was washed with saturated sodium bicarbonate, extracted 3x with EtOAc.  
The organic layer was washed with brine, dried over sodium sulfate, and filtered. The 
filtrate was concentrated and purified by flash column chromatography (coupled 
product eluted with 90% EtOAc in hexanes).  The coupled tbutyl ester was carried 
forward with no further purification.   
TFA (0.5 mL) was added to the tbutyl ester dissolved in DCM (1 mL).  The reaction 
was stirred until complete by TLC (30 min).  The reaction was dried in vacuo to remove 
excess TFA.  The carboxylic acid was purified by flash column chromatography 
(eluted with 8% MeOH in DCM) to give a white solid (0.043 g, 42% 2 step yield); 1H 
NMR (500 MHz, DMSO-d6) δ 7.71 (d, J = 7.3 Hz, 1H), 7.56 (t, J = 7.5 Hz, 1H), 7.50 – 
7.46 (m, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.23 (dd, J = 8.3, 2.0 
Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.38 (bs, 2H), 6.21 (bs, 2H), 3.88 (s, 3H), 3.85 (s, 
2H), 2.55 (q, J = 7.5 Hz, 2H), 1.04 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
170.3, 164.9, 156.4, 141.2, 133.5, 132.8, 131.2, 130.8, 129.5, 129.2, 128.2, 127.3, 
125.1, 110.7, 95.7, 88.6, 76.7, 56.0, 29.1, 21.1, 12.8; HRMS (DART [M+H]+) m/z 
403.1744  (calculated for C23H23N4O3 403.1770). 
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6-Ethyl-5-[3-(2-methoxy-5-(3-carboxyphenyl)-phenyl)-prop-1-ynyl]-pyrimidine-
2,4-diamine-trifluoroacetate salt (3b). In a screw cap vial fitted with a stir bar and a 
septum, was added alkyne (0.10 g, 0.31 mmol), iodo-ethylpyrimidine (0.06 mg, 0.24 
mmol), Pd(PPh3)2Cl2 previously doped with 10% CuI by weight (0.01 g, 0.02 mmol), 
and KOAc (0.23 g, 2.38 mmol). DMF (3 mL) was added and argon was bubbled 
through the stirring solution for 10 min. The vial was sealed and heated to 50 °C until 
complete by TLC (2-3 h).  The reaction was dried in vacuo using toluene as an 
azeotrope.  The residue was washed with saturated sodium bicarbonate, extracted 3x 
with EtOAc.  The organic layer was washed with brine, dried over sodium sulfate, and 
filtered. The filtrate was concentrated and purified by flash column chromatography 
(coupled product eluted with 90% EtOAc in hexanes).  The coupled tbutyl ester was 
carried forward with no further purification.   
TFA (0.5 mL) was added to the tbutyl ester dissolved in DCM (1 mL).  The reaction 
was stirred until complete by TLC (30 min).  The reaction was dried in vacuo to remove 
excess TFA.  The carboxylic acid was purified by flash column chromatography 
(eluted with 8% MeOH in DCM) to give a white solid (0.48 g, 53% yield 2 steps). 
Compound isolated as the TFA salt; 1H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H), 
8.16 (s, 1H), 7.91 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.78 – 7.75 (m, 1H), 
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7.73 (s, 1H), 7.67 – 7.63 (m, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 
3.93 (s, 2H), 3.91 (s, 3H), 2.71 (q, J = 7.5 Hz, 2H), 1.18 (t, J = 7.6 Hz, 3H); 13C NMR 
(126 MHz, DMSO) δ 167.7, 164.9, 164.9, 159.0 (q, J = 31.3), 157.0, 154.5, 140.6, 
131.9, 131.0, 129.8, 128.1, 127.6, 127.2, 127.0, 125.3, 111.8, 98.6, 91.8, 72.2, 56.2, 
25.6, 21.0, 12.4; HRMS (DART [M+H]+) m/z 403.1748 (calculated for C23H23N4O3 
403.1770). 
 
6-Ethyl-5-[3-(2-methoxy-5-(4-carboxyphenyl)-phenyl)-prop-1-ynyl]-pyrimidine-
2,4-diamine (3c). In a screw cap vial fitted with a stir bar and a septum, was added 
alkyne (0.10 g, 0.31 mmol), iodo-ethylpyrimidine (0.06 mg, 0.24 mmol), Pd(PPh3)2Cl2 
previously doped with 10% CuI by weight (0.01 g, 0.02 mmol), and KOAc (0.23 g, 2.38 
mmol). DMF (3 mL) was added and argon was bubbled through the stirring solution 
for 10 min. The vial was sealed and heated to 50 °C until complete by TLC (2-3 h).  
The reaction was dried in vacuo using toluene as an azeotrope.  The residue was 
washed with saturated sodium bicarbonate and extracted 3x with EtOAc.  The organic 
layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was 
concentrated and purified by flash column chromatography (coupled product eluted 
with 90% EtOAc in hexanes).  The coupled tbutyl ester was carried forward with no 
further purification.   
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TFA (0.5 mL) was added to the tbutyl ester dissolved in DCM (1 mL).  The reaction 
was stirred until complete by TLC (30 min).  The reaction was dried in vacuo to remove 
excess TFA.  The carboxylic acid was purified by flash column chromatography 
(eluted with 8% MeOH in DCM) to give a white solid (0.039 g, 43% yield 2 steps); 1H 
NMR (500 MHz, CDCl3: Methanol-d4) δ 8.08 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 2.3 Hz, 
1H), 7.68 (d, J = 8.4 Hz, 2H), 7.61 (dd, J = 8.5, 2.4 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 
3.95 (s, 3H), 3.95 (s, 2H), 2.79 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H); 13C NMR 
(126 MHz, DMSO) δ 171.8, 165.0, 161.6, 157.3, 144.2, 131.7, 130.4, 127.9, 127.7, 
127.0, 126.5, 126.3, 111.7, 95.7, 88.5, 76.9, 56.2, 29.3, 21.1, 11.0; HRMS (DART 
[M+H]+) m/z 403.1746 (calculated for C23H23N4O3 403.1770). 
 
6-Ethyl-5-[3-(3-methoxy-5-(4-carboxyphenyl)-phenyl)-prop-1-ynyl]-pyrimidine-
2,4-diamine-trifluoroacetate salt (3d). In a screw cap vial fitted with a stir bar and a 
septum, was added alkyne (0.10 g, 0.31 mmol), iodo-ethylpyrimidine (0.06 mg, 0.24 
mmol), Pd(PPh3)2Cl2 previously doped with 10% CuI by weight (0.01 g, 0.02 mmol), 
and KOAc (0.23 g, 2.38 mmol). DMF (3 mL) was added and argon was bubbled 
through the stirring solution for 10 min. The vial was sealed and heated to 50 °C until 
complete by TLC (2-3 h).  The reaction was dried in vacuo using toluene as an 
azeotrope.  The residue was washed with saturated sodium bicarbonate and extracted 
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3x with EtOAc.  The organic layer was washed with brine, dried over sodium sulfate, 
and filtered. The filtrate was concentrated and purified by flash column 
chromatography (coupled product eluted with 90% EtOAc in hexanes).  The coupled 
tbutyl ester was carried forward with no further purification.   
TFA (0.5 mL) was added to the tbutyl ester dissolved in DCM (1 mL).  The reaction 
was stirred until complete by TLC (30 min).  The reaction was dried in vacuo to remove 
excess TFA.  The carboxylic acid was purified by flash column chromatography 
(eluted with 8% MeOH in DCM) to give as a white solid (0.045 g, 49% yield 2 steps). 
Compound isolated as the TFA salt; 1H NMR (500 MHz, DMSO-d6) δ 7.5-7.0 (bs, 4H), 
8.04 (d, J = 7.7 Hz, 2H), 7.81 (d, J = 7.7 Hz, 2H), 7.36 (s, 1H), 7.18 (s, 1H), 7.06 (s, 
1H), 4.01 (s, 2H), 3.86 (s, 3H), 2.75 – 2.61 (m, 2H), 1.18 (t, J = 7.4 Hz, 3H); 13C NMR 
(126 MHz, DMSO) δ 167.6, 164.9, 160.5, 158.6 (q, J = 31.3), 144.6, 141.1, 139.5, 
130.4, 127.4, 119.5, 114.1, 111.1, 98.0, 90.8, 73.4, 55.8, 26.5, 26.0, 12.6; HRMS 
(DART [M+H]+) m/z 403.1777 (calculated for C23H23N4O3 403.1770). 
HPLC Purity Analysis 
Purity analysis were performed with a reversed phase high performance liquid 
chromatography on a Shimadzu Prominence 20 instrument fitted with a Luna 5μ 
C18(2) 100 Ǻ column (5 μM, 4.6 mm x 250 mm, Phenomenex) and using UV diode 
array detection at 254 nm. Two separate determinations (Method A: isocratic: 
40/60/0.1 MeCN/H2O/TFA and Method B: isocratic: 60/40/0.1 MeOH/H2O/TFA or 
80/20/0.1 MeOH/H2O/TFA) were made to determine compound purity. Flow rate was 
1.0 mL/min for Method A and 1.0 mL/min for Method B. Compounds were diluted in 
71 
 
HPLC grade methanol and filtered prior to analysis. Sample concentrations were 1 
mg/ml. All final tested compounds were at least 95% pure according to both methods. 
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3 Design and Development of a New PLA Scaffold: B-ring deleted chain 
PLAs as Effective Non-Classical Antifolates  
3.1 Preface 
 
Contributions: My contributions to this chapter were the design and synthesis of the 
chain PLAs.  Michael Lombardo provided the biological activity data against E. coli 
and the crystal structure of UCP1103 bound to E. coli.  Stephanie Reeve provided 
biological activity data against S. aureus. 
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3.2 PLAs and Gram-negative Pathogens 
Infections by Gram-negative bacteria pose a significant challenge to drug 
discovery programs tasked with finding new therapies to treat them.  While discovering 
new drugs to treat Gram-positive bacteria is difficult, Gram-negative bacteria pose a 
greater challenge largely due to the inability of many Gram-positive antibacterials to 
enter the Gram-negative cell.1  Combined with an ever present threat of acquired 
resistance, it is no surprise that two of the three microorganisms classified by the CDC 
as ‘urgent’ are Gram-negative bacteria.2   
Antifolates, such as Trimethoprim (TMP) and sulfamethoxazole (SMX, 
administered as Bactrim), are used clinically to treat skin and soft tissue infections and 
uncomplicated urinary tract infections caused by Escherichia coli and Klebsiella 
pneumoniae.  TMP inhibits dihydrofolate reductase (DHFR) and SMX inhibits 
dihydropteroate synthase (DHPS).  Both are essential enzymes in the folate pathway 
responsible for converting dihydrofolate (DHF) to tetrahydrofolate (THF).3  Recently, 
Bactrim resistance has reduced its use clinically in favor of nitrofurantoin and 
fluoroquinolones.4 Unsurprisingly, fluoroquinolone resistance has followed, 
complicating its use in treating more serious infections.5  With Enterobacteriaceae 
resistance growing and TMP use declining, antifolates represent an opportunity for 
new therapies.  
We have been developing a new class of propargyl-linked antifolates (PLA) as 
DHFR inhibitors based on modifications to TMP’s structure.  We have observed 
excellent enzyme and growth inhibition against methicillin-resistant Staphyloccocus 
aureus (MRSA),6,7 as well as against clinically relevant TMP-resistant DHFR mutants.8  
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We have also observed excellent MIC activity against Mycobacterium tuberculosis, 
both multi-dug resistant (MDR) and extensively drug resistant (XDR).9 Unfortunately, 
we have seen a dramatic reduction in MIC activity against Enterobacteriaceae. We 
have previously reported PLAs with good MIC activity against K. pneumoniae10,11 
however E. coli activity is reduced due to the problems associated with antibacterial 
entry into the Gram-negative cell. 
3.3 Entry into Gram-negative Bacterial Cells  
 
Figure 3.1 Gram-negative Outer Membrane Restricts Entry of Many Drugs Capable 
of Targeting Gram-positive Bacteria1 
78 
 
It is well known that antibacterial penetration into Gram-negative bacteria is a 
notoriously difficult problem in drug discovery.12  While Gram-positive bacteria 
possess a cytoplasmic membrane that acts as a filter to highly charged compounds, 
Gram-negative bacteria possess an additional outer membrane (OM) that acts to slow 
penetration of lipophilic compounds into the cell (Figure 3.1).  This orthogonal filtering 
mechanism is significant for the loss in activity of many clinically used Gram-positive 
antibacterials against Gram-negative pathogens. 
 
The OM structure is made of a lipid bilayer with ordered lipopolysaccharide (LPS) 
making up the outer leaflet (Figure 3.2).  The LPS layer is highly negatively charged, 
making passive diffusion through the OM difficult compared to a typical lipid bilayer.13  
While passive diffusion is possible, many clinically used antibacterials penetrate the 
OM through porins, small channels that traverse the OM. Porins allow small, highly 
charged solutes to enter into the periplasmic space between the OM and inner 
Figure 3.2 Gram-negative Bacterial Outer Membrane (OM) Architecture19 
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membrane (IM).  Efflux pumps, multi-protein complexes that span from the OM, 
through the perisplasm, and anchor to the IM, are working to eject solutes into the 
extracellular space. Together, the OM and efflux pumps work synergistically to limit 
accumulation of drug concentration in the cell.12,14-15 
To overcome the difficulties presented by Gram-negative OM penetration, many 
have examined the physicochemical properties of clinically used Gram-negative 
antibacterials to identify structure-activity relationships (SAR).  Molecular weight and 
lipophilicity, measured by the octanol water partition coefficient (logP), have been 
identified as physical properties that diverge from Gram-positive antibacterials and 
other clinically used therapeutics (Figure 3.3).  Nikaido reported the size exclusion 
limit of the OM was 600 daltons, an often cited number that is not absolute.16 Nikaido 
also reported that much larger but more flexible polyethyleneglycols were able to 
penetrate the OM, meaning that flexibility and shape must play a role in penetration 
as well.   
Figure 3.3 Physical Properties Play a Significant Role in Entry Through the OM.  The 
red circle denotes where traditional PLAs fall on the chart 
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PLAs have traditionally been highly lipophilic, inflexible compounds with molecular 
weights above 400 daltons.  Here, we report the design, synthesis, and biological 
activity of chain PLAs.  By removing the B-ring, we can retain the necessary enzyme 
interactions of the diaminopyrimidine and the varied C-rings, while removing a large, 
hydrophobic, and rigid benzene in favor of a carbon chain.  This will have the effect of 
bringing the physicochemical properties of this new generation of PLAs closer to what 
is believed to be ideal for Gram-negative cellular penetration. 
3.4 Design and Synthesis of Chain PLAs 
 
We began by modifying a previously reported PLA with nanomolar Gram-positive 
antibacterial activity and poor Gram-negative antibacterial activity, UCP1021 
(Scheme 3.1).  We envisioned removing the methoxybenzene B-ring and leaving the 
carbon chain connecting the diaminopyrimidine to a distal pyridine. To determine the 
ideal chain length three compounds bearing butynyl-, pentynyl-, and hexynyl-linked 
chains were synthesized.  For the truncated butynyl compound 7, we performed a 
Scheme 3.1 Design of Chain PLAs from Parent PLAs 
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Horner-Wadsworth-Emmons reaction to generate the ester with the proper chain 
length (Scheme 3.2).  Catalytic hydrogenation, ester reduction, and subsequent re-
oxidation gave aldehyde 5.  Typical Ohira-Bestmann alkyne synthesis gave 6, which 
was coupled to the diaminopyrimidine via Sonogashira coupling to give 7.  For 
pentynyl-linked 4a and butynyl-linked 9, we knew we could access both from the 
common aldehyde 2a.  From 1a, Wittig homologation installed the aldehyde 
functionality directly via the protected acetal.  Catalytic hydrogenation and acetal 
cleavage gave the desired aldehyde 2a.  Alkyne synthesis gave 3a which 
subsequently underwent Sonogashira coupling to generate pentynyl-linked 4a.  From 
2a, a one carbon Wittig homolgation and enol ether cleavage yielded the extended 
aldehyde which was subjected to Ohira-Bestmann homologation to give alkyne 8.  
Sonogashira coupling yielded the desired hexynyl-linked 9.  Biological evaluation 
determined that the pentynyl-linked 4a was the most active compound (Table 3).  
Subsequent compounds 4b-c were synthesized exclusively as the pentynyl-linked 
variants.   
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3.5 Chain PLA Biological Activity 
We were pleased that all three compounds maintained potent enzyme activity 
(Table 3), with 4a being as potent as UCP1021, 19 nm and 21 nm respectively.  
However, we saw a significant loss in growth inhibition activity of all three compounds 
compared to UCP1021.  Compound 4a was the most potent of the three chain 
compounds as a 0.625 µg/ml inhibitor, compared to UCP1021 which is a 0.023 µg/ml 
inhibitor.   
Scheme 3.2 Synthesis of Chain PLAs 
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Against EcDHFR, all three chain compounds showed increased enzyme activity 
relative to UCP1021, an 830 nM inhibitor.  Compounds 9 and 7 showed a 4-fold 
increase in activity, 211 nm and 204 nm respectively, while 4a saw a 15-fold increase 
in activity.  Compound 4a also showed the best growth inhibition activity against 
Ec25922 at 6.25 µg/ml, at least a 3.2-fold increase compared to UCP1021. Compound 
7 showed moderate activity with an MIC of 10 µg/ml, while 9 showed no activity at >50 
µg/ml.  The data suggested that going forward, we should pursue three atom linkages 
between the acetylene and the C-ring.   
To determine if the chain compounds were penetrating through the outer 
membrane of E. coli, we tested them against a wild-type E. coli strain, BW25113, a 
ΔacrB strain, JW0451, and an engineered strain with a deletion in the imp gene, that 
encodes a protein necessary for outer membrane assembly, NR698.  This panel of 
strains offers insight into the mechanism most responsible for the loss in activity of our 
compounds against E. coli. A large activity loss between NR698 and JW0451 would 
lead us to believe that compound permeability through the outer membrane is 
responsible. A compound with a large activity loss between JW0451 and BW25113 
would indicate that the compound is an efflux substrate. 
When comparing 4a to UCP1021 we see that they have similar activity against 
NR698 (0.0391 µg/ml vs 0.07813 µg/ml); however, there is a significant difference 
between the two compounds against JW045 (0.3125 µg/ml vs. 2.5 µg/ml).  This 
indicates that 4a is penetrating the outer membrane more than its B-ring counterpart, 
UCP1021.  This is further confirmed when comparing the BW25113 parent strain 
activity (15 µg/ml vs. 20 µg/ml).  The fact that these two compounds have similar 
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activity in the LPS knockout strain, and the WT BW25113 strain, indicates that the 
difference observed in the JW0451 strain is likely due to the ability of 4a to penetrate 
the outer membrane of E.coli better than UCP1021.  Comparing their physicochemical 
properties we see that 4a has a lower MW than UCP1021 (281.36 vs. 359.43) and 
also a lower cLogP (2.47 vs. 3.33), supporting our initial hypothesis. 
Compound 4d, with a three-carbon linker between the alkyne and a distal 
phenol, was synthesized as a direct comparator against UCP1128, its B-ring 
counterpart.  While both were inactive against the ATCC test strain, 4d showed 
increased activity against BW25113 compared to UCP1128 (10 µg/ml vs. >20 µg/ml). 
Little difference was seen between the two compounds in the JW0451 strain, 
indicating there is likely no difference in their ability to penetrate the outer membrane 
of E.coli.  However, an almost 10-fold difference was seen in the NR698 strain (0.0195 
µg/ml vs. 0.156 µg/ml).  This could be due to 4d being a better EcDHFR inhibitor than 
UCP1128; however, incomplete data leaves this conclusion unconfirmed. 
Table 4. Chain PLA Scaffold and Biological Activity 
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Both 4a and 4d showed that removal of the B-ring in traditional PLAs led to better 
enzyme inhibition and an increase in cellular potency against E.coli, as measured by 
MIC. Compound 4a in particular gave substance to our original hypothesis that 
reducing MW and cLogP of our traditional PLAs could increase E. coli penetration and 
growth inhibition.  Compounds 4a and 4d also showed promising activity against S. 
aureus, with 4d having a superior IC50 and MIC with value of 10 nM and MIC of 0.156 
µg/ml, respectively.   
       
 
Figure 3.4 Crystal Structure of 4a (magenta) Bound to wt E.coli DHFR.  
 Compound 4a is shown bound to WT E.coli DHFR displaying the common 
diaminopyrimidine motif (Figure 3.4).  Asp27 makes hydrogen bonding contacts with 
two nitrogens of the ring, while the protonated nitrogen makes a hydrogen bonding 
interaction with a water molecule.  Lys38 and the carbonyl of Ile5 make hydrogen-
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bonding contacts with the other two nitrogen atoms in the diaminopyrimidine ring.  
Phe31 makes a π-π interaction with the acetylenic linker.  No electron density is seen 
in the NADPH binding pocket which sits above the propargylic position of the inhibitor.  
The absence of NADPH could be an artifact of the crystallization conditions, however 
it could also give insight into the activity of 4a.  If 4a can bind without NADPH being 
present, it is possible that its activity is owed to the removal of the natural co-factor 
from the active site. Interestingly, the distal pyridine ring makes a hydrogen bonding 
interaction with a sulfate anion, which is stabilized by further hydrogen bonding 
contacts with Lys32 and Arg57.  This is certainly unusual and has implications for 
further drug design. By incorporating functionality at this extended position that can 
accompany multiple hydrogen bond contacts we could design better enzyme inhibitors 
and ultimately better leads. 
We have shown a modified scaffold, based on our previously reported PLA lead 
compounds, consisting of a removed B-ring, with either all-carbon or heteroatom-
containing chain connecting the acetylenic linker to the variable “C-ring”.  We 
determined the optimal atom length of the chain, which is possibly variable depending 
on the C-ring substitution.  Our hypothesis of reducing LogP and MW to increase 
penetration into the Gram-negative bacterial cell was supported when comparing 
chain compounds 4a and 4d to their B-ring parent compounds.  These inhibitors show 
moderate activity against E. coli and could be improved upon going forward. 
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3.6 Experimentals 
 
The 1H and 13C NMR spectra were recorded on Bruker instruments at 500 MHz. 
Chemical shifts are reported in ppm and are referenced to residual CHCl3 solvent; 
7.24 and 77.23 ppm for 1H and 13C, residual solvent MeOH; 4.78, 3.31 and 49.15 ppm 
respectively. The high-resolution mass spectrometry was provided by the University 
of Connecticut Mass Spectrometry Laboratory using AccuTOF mass spectrometer 
and/or using DART source. TLC analyses were performed on Sorbent Technologies 
silica gel HL TLC plates. All glassware was oven-dried and allowed to cool under an 
argon atmosphere. Anhydrous dichloromethane, and tetrahydrofuran were used 
directly from Baker Cycle-Tainers. All reagents were used directly from commercial 
sources unless otherwise stated.  
 
3-(Pyridin-4-yl)propanal (5). A 25-mL flask was flame dried under argon.  Once at rt, 
NaH (18.67 mmol, 0.45 g) was suspended in THF (25 mL) and cooled to 0 °C. 
Triethylphosphonoacetate (9.34 mmol, 2.09 g) was added and stirred at 0 °C  for 15 
minutes.  A solution of 4-pyridinecarboxaldehyde (4.67 mmol, 0.50 g) in THF (2 mL) 
was added dropwise and stirred at 0 °C for 30 minutes before slowly warming to rt. 
The reaction was complete by TLC after 1 hour.  The reaction was quenched by 
addition of saturated NH4Cl and extracted with EtOAc (3x15 mL).  The organic layer 
was dried and the solvent was removed to give a crude oil that was used without 
further purification.   
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In a 50 mL flask, the crude oil was dissolved in MeOH (15 mL) and added to a RB 
flask containing 10% Pd/C (0.33 mmol, 0.036 g).  The flask was evacuated and back-
filled with H2 for five cycles.  The reaction was allowed to stir until complete by TLC.  
The reaction was filtered through celite, washed with EtOAc, and the solvent was 
removed to give a crude oil that was used without further purification. 
In a 50 mL flask, the crude oil was dissolved in MeOH (20 mL) and NaBH4 (5.02 mmol, 
0.19 g) added.  The reaction was stirred at 60 °C until complete by TLC (be sure to 
appropriately vent flask to allow for H2 evolution).  Saturated NH4Cl was added and 
the mixture was extracted with EtOAc (3x20 mL).  The organic layer was dried, the 
solvent was removed, and the crude oil was used without further purification. 
In a 50 mL flask, the crude oil dissolved in DCM (20 mL) and Dess-Martin periodinane 
(3.33 mmol, 1.41 g) was added with stirring until complete by TLC.  Saturated sodium 
thiosulfate was added and extracted with EtOAc (3x15 mL). The organic layer was 
dried, the solvent was removed, and the aldehyde was purified via column 
chromatography (eluted in 50:50 EtOAc:Hexanes) to give a slight yellow oil (0.31 g, 
50% yield over 4 steps).  NMR data agreed with previous reports.17  
 
4-(But-3-ynyl)pyridine (6).  General Ohira-Bestmann Homologation Method 
To a dried 25 mL flask under argon was added K2CO3 (0.86 mmol, 0.12 g) and 5 mL 
MeOH and cooled to 0 °C.  Dimethyl (1-diazo-2-oxopropyl)phosphonate (0.60 mmol, 
0.12 g) was added and stirred for 15 minutes.  Pyridine-4-propanal 5 (0.57 mmol, 0.08 
g) was added and stirred until complete by TLC.  Brine was added to quench the 
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reaction and the aqueous layer was extracted with EtOAc (3x10 mL).  The organic 
layer was dried, the solvent was removed, and the alkyne was purified via column 
chromatography (eluted in 30:70 EtOAc:Hexanes) to give a yellow oil (0.06 g, 75%).  
1H NMR (500 MHz, CDCl3) δ 8.64 – 8.42 (m, 2H), 7.16 (d, J = 5.2 Hz, 2H), 2.83 (t, J 
= 7.3 Hz, 2H), 2.51 (td, J = 7.3, 2.5 Hz, 2H), 1.99 (t, J = 2.5 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 149.9, 149.2, 124.0, 82.9, 69.8, 34.0, 19.5. 
 
6-Ethyl-5-(4-(pyridin-4-yl)but-1-ynyl)pyrimidine-2,4-diamine (7). General Method 
for Sonogashira Coupling. 
In a 20 mL vial, pyridine-4-propyne (0.35 mmol, 0.05 g), 6-ethyl,5-iodo 2,4-
diaminopyrimidine (0.26 mmol, 0.07 g), Pd(PPh3)4Cl2 (0.026 mmol, 0.018 g), and CuI 
(0.052 mmol, 0.010 g) were added.  To the solids was added DMF (2 mL) and Et3N 
(1 mL), followed by degassing via 3 freeze-pump-thaw cycles.  The reaction was 
heated to 65 °C for 16 h.  Once complete by TLC, DMF was removed via multiple 
toluene azeotropes.  Once dried, the reaction mixture was pre-absorbed onto a 1:1 
mixture of SiO2 and NH2-capped SiO2. PLA 7 was purified via column chromatography 
(eluted in 2% MeOH in DCM) to give a slight yellow solid (0.025 g, 35%).  1H NMR 
(500 MHz, MeOD:CDCl3) δ 8.45 (s, 2H), 7.33 (d, J = 5.2 Hz, 2H), 2.97 (t, J = 6.9 Hz, 
2H), 2.88 (t, J = 6.8 Hz, 2H), 2.49 (q, J = 7.6 Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H);  13C 
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NMR (126 MHz, MeOD:CDCl3) δ 172.6, 164.5, 160.6, 151.0, 148.9, 124.6, 97.0, 90.1, 
74.2, 34.2, 29.2, 20.3, 12.4. 
 
 
 
4-(Pent-4-ynyl)pyridine (3a). General method for pentynyl – chain synthesis 
A 25-mL flask was flame dried under argon.  Once at rt, 2(1,3-dioxolan-2-yl) ethyl-
triphenylphosphonium chloride (9.66 mmol, 4.28 g) was dissolved in THF (6 mL) and 
cooled to -30 °C. nBuLi (9.66 mmol, 3.86 mL, 2.5 M in hexanes) was added dropwise 
and allowed to stir for 30 minutes.  A solution of 4-pyridinecarboxaldehyde (8.40 mmol, 
0.90 g) in THF (1 mL) was added dropwise and stirred at -30 °C for 30 minutes before 
slowly warming to rt.  The reaction was complete by TLC after 2 hours.  The reaction 
was quenched by addition of saturated NH4Cl.  The aqueous layer was extracted with 
EtOAc (3x10 mL).  The combined organic layers were dried and the solvent was 
removed to give a crude oil that was used without further purification.    
In a 50 mL flask, the crude oil was dissolved in MeOH (30 mL) and added to flask 
containing 10% Pd/C (1.00 mmol, 0.108 g). The flask was evacuated and back-filled 
with H2 for five cycles.  The reaction was allowed to stir until complete by TLC.  The 
reaction was filtered through celite, washed with EtOAc, and the solvent was removed 
to give a crude oil that was used without further purification. 
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In a 100 mL flask, the crude oil was dissolved in AcOH:H2O (50 mL of 80:20) and 
heated to 65 °C until complete by TLC. Once complete, the solvent was removed and 
the material was purified by column chromatography (eluted in 50:50 Hexanes:EtOAc) 
to give a slight yellow oil (0.75 g, 60%).  NMR characterization matched previous 
reports in the literature.18 
The aldehyde was subjected to the General Ohira-Bestmann Homologation method 
to generate the title alkyne as a yellow oil (0.09 g, 62%).  1H NMR (500 MHz, CDCl3) 
δ 8.43 (d, J = 5.5 Hz, 2H), 7.07 (d, J = 5.5 Hz, 2H), 2.72 – 2.65 (m, 2H), 2.15 (td, J = 
6.9, 2.6 Hz, 2H), 1.98 (t, J = 2.6 Hz, 1H), 1.79 (p, J = 7.2 Hz, 2H);  13C NMR (126 MHz, 
CDCl3) δ 150.5, 149.8, 124.0, 83.6, 69.4, 33.9, 28.9, 17.9. 
 
5-(Pent-4-ynyl)pyrimidine (3b). Synthesized according to the “General method for 
pentynyl-chain synthesis” to give title alkyne as a yellow oil (0.11 g, 35% from 4b): 1H 
NMR (500 MHz, CDCl3) δ 9.06 (s, 1H), 8.59 (s, 2H), 2.79 – 2.70 (m, 2H), 2.23 (td, J = 
6.8, 2.6 Hz, 2H), 2.02 (t, J = 2.6 Hz, 1H), 1.85 (dt, J = 14.4, 6.9 Hz, 2H); 13C NMR (126 
MHz, CDCl3) δ 157.1, 156.9, 134.5, 83.1, 69.8, 53.2, 29.2, 17.8. 
 
tert-Butyl 4-(pent-4-ynyl)benzoate (3c). Synthesized according to the “General 
method for pentynyl-chain synthesis” to give title alkyne as a yellow oil (0.150 g, 32% 
from 4d): 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 7.9 Hz, 
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2H), 2.81 (t, J = 7.6 Hz, 2H), 2.21 (td, J = 6.9, 2.6 Hz, 2H), 2.03 (t, J = 2.7 Hz, 1H), 
1.87 (p, J = 7.1 Hz, 2H), 1.61 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 165.8, 146.4, 
129.9, 129.6, 128.4, 83.8, 80.7, 69.0, 34.5, 29.7, 28.2, 17.8. 
 
4-(Pent-4-ynyl)phenol (3d). Synthesized according to the “General method for 
pentynyl-chain synthesis” to give title alkyne as a yellow oil (0.150 g, 32% from 4c): 
1H NMR (500 MHz, CDCl3) δ 7.11 (d, J = 8.3 Hz, 2H), 6.81 (d, J = 8.4 Hz, 2H), 2.71 
(t, J = 7.5 Hz, 2H), 2.23 (td, J = 7.0, 2.6 Hz, 2H), 2.04 (t, J = 2.6 Hz, 1H), 1.85 (p, J = 
7.1 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 153.7, 133.8, 129.6, 115.2, 84.3, 68.7, 
33.7, 30.3, 17.7. 
 
4-(Hex-5-ynyl)pyridine (8). To a 0 °C suspension of methoxymethyl-
triphenylphosphonium chloride (2.68 mmol, 0.92 g,) in THF (10 mL) under an argon 
atmosphere was added NaOtBu (2.68 mmol, 0.26 g) in one portion. The red-orange 
suspension was stirred for 30 minutes at 0 °C.  Pyridine-4-butanal 2a (1.34 mmol, 0.20 
g) was added in THF (2 mL) and stirred at 0 °C until complete by TLC.  The reaction 
was quenched with H2O and extracted with EtOAc (3x15 mL).  The organic layer was 
dried and the solvent was removed to give a crude oil that was used without further 
purification. 
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The crude oil was dissolved in MeCN (8 mL) under an argon atmosphere.  Sodium 
iodide (0.47 mmol, 0.70 g) was added and cooled to -20 °C.  TMSCl (0.47 mmol, 0.06 
mL) was added and stirred at -20 °C until complete by TLC.  The reaction was diluted 
with EtOAc (10 mL) and saturated sodium thiosulfate was added. The reaction stirred 
as it warmed to rt.  The mixture was extracted with EtOAc (3x15 mL), the combined 
organic layers were dried, and the solvent was removed to give a crude oil that was 
used without further purification. 
The general Ohira-Bestmann alkyne homologation method was followed to synthesize 
the title alkyne 8 as a slightly yellow oil (0.07 g, 33% over 3 steps): 1H NMR (500 MHz, 
CDCl3) δ 8.50 (d, J = 5.9 Hz, 2H), 7.13 (d, J = 5.9 Hz, 2H), 2.65 (t, J = 7.7 Hz, 2H), 
2.25 (td, J = 7.0, 2.6 Hz, 2H), 1.98 (t, J = 2.6 Hz, 1H), 1.78 (p, J = 7.6 Hz, 2H), 1.59 
(dt, J = 14.8, 7.1 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 151.2, 149.9, 124.0, 82.2, 
68.8, 34.8, 29.3, 28.0, 18.4. 
 
6-Ethyl-5-(5-(pyridin-4-yl)pent-1-ynyl)pyrimidine-2,4-diamine (4a). Synthesized 
according to the “General method for Sonogashira Coupling” to give title compound 
as a pale yellow solid (0.018 g, 37%): 1H NMR (500 MHz, CDCl3) δ 8.48 (d, J = 5.9 
Hz, 2H), 7.16 (d, J = 5.8 Hz, 2H), 2.83 – 2.75 (m, 2H), 2.68 (q, J = 7.6 Hz, 2H), 2.51 
(t, J = 6.9 Hz, 2H), 1.95 (p, J = 7.0 Hz, 2H), 1.24 (t, J = 7.7 Hz, 5H). 
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6-Ethyl-5-(5-(pyridin-4-yl)hex-1-ynyl)pyrimidine-2,4-diamine (9). Synthesized 
according to the “General method for Sonogashira Coupling” to give title compound 
as a pale yellow solid (0.014 g, 24%):  NMR data not available 
 
 
6-Ethyl-5-(5-(pyrimidin-5-yl)pent-1-ynyl)pyrimidine-2,4-diamine (4b). 
Synthesized according to the “General method for Sonogashira Coupling” to give title 
compound as a yellow solid (0.022 g, 31%): 1H NMR (500 MHz, CDCl3) δ 9.12 (s, 1H), 
8.65 (s, 2H), 5.19 (s, 2H), 4.93 (s, 2H), 2.82 (t, J = 7.7 Hz, 2H), 2.71 (q, J = 7.6 Hz, 
2H), 2.56 (t, J = 6.9 Hz, 2H), 1.98 (p, J = 7.0 Hz, 2H), 1.26 (t, J = 7.6 Hz, 3H). 
 
4-(5-(2,4-Diamino-6-ethylpyrimidin-5-yl)pent-4-ynyl)benzoic acid (4c). 
Synthesized according to the “General method for Sonogashira Coupling” to give title 
compound as a yellow solid (0.025 g, 38%): 1H NMR (500 MHz, DMSO-d6) δ 7.88 (d, 
95 
 
J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 2.79 (t, J = 7.6 Hz, 2H), 2.67 (q, J = 7.5 Hz, 
2H), 2.49 (d, J = 7.1 Hz, 2H), 1.90 (p, J = 7.2 Hz, 2H), 1.21 (d, J = 7.6 Hz, 3H). 
 
4-(5-(2,4-Diamino-6-ethylpyrimidin-5-yl)pent-4-ynyl)phenol (4d). Synthesized 
according to the “General method for Sonogashira Coupling” to give title compound 
as a yellow solid (0.027 g, 44%): 1H NMR (500 MHz, CDCl3) δ 7.06 (d, J = 8.3 Hz, 
2H), 6.78 (d, J = 8.3 Hz, 2H), 2.70 (dt, J = 12.2, 7.5 Hz, 4H), 2.48 (t, J = 7.0 Hz, 2H), 
1.90 (p, J = 7.1 Hz, 2H), 1.25 (t, J = 7.6 Hz, 3H). 
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4 Direct Substitution of Arylalkynyl Carbinols Provides Convenient Access 
to Diverse Terminal Acetylene Building Blocks 
4.1 Preface 
 
The following chapter is taken from the following publication: 
G-Dayanandan, N.,† Scocchera, E. W.,† Keshipeddy, S., Jones, H. F., Anderson, A. 
C., Wright, D. L.; Direct Substitution of Arylalkynyl Carbinols Provides Access to 
Diverse Terminal Acetylene Building Blocks. Org. Lett. 2016, acs.orglett.6b03438. 
†Authors contributed equally 
 
Contributions:  My contribution to the work is the idea of a divergent synthesis from 
a common propargyl alcohol intermediate, the implementation of the Reetz chemistry, 
and the synthesis of the geminal dimethyl substituted compounds as well as two of 
the singly-methylated propargyl compounds.  Narendran G-Dayanandan implemented 
the deoxygenation of propargyl alcohols and synthesized the propargyl unsubstituted 
compounds and the other singly-methylated compounds.   
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4.2 Introduction and Alkyne Utility  
 The incorporation of alkyne functionality in screening libraries,1-4 biological 
probes,5,6 and therapeutic agents7,8 is becoming increasingly prevalent.  This is due 
to both the relative ease of their incorporation into complex molecules, through cross-
coupling chemistry9-12 and azide “click” cycloadditions13 and their distinct topological 
features.  While aryl alkynes are often observed in the literature, alkyl alkynes bearing 
a propargyl position capable of functionalization are less common.  This is likely due 
to the propensity of alkynes to isomerize to allenes under mild conditions.  In fact, a 
Scifinder literature survey showed a plethora of arylalkynyl carbinols in biologically 
relevant molecules.  This motif is likely generated from nucleophilic alkyne addition to 
carbonyls without subsequent alteration of the resulting propargyl alcohol.  It is 
worthwhile to ask whether there is a biological importance to the propargyl alcohol 
functionality or if it is included simply due to synthetic ease.  Nicholas developed a 
method to mask alkyne functionality using dicobalt octacarbonyl (Co2(CO8))14,15 while 
the propargyl position underwent functionalization, with a subsequent deprotection 
once the propargyl functionality was set.  While it has been utilized to synthesize 
bioactive molecules,16,17 it is far from an ideal solution from a synthetic perspective.   
100 
 
4.3 PLAs and Their Synthesis  
 A structure-based drug design approach has led to a series of propargyl-linked 
antifolates (PLAs) characterized by the insertion of a propargylic linker18-20 between a 
2,4-diaminopyrimidine A ring and a hydrophobic B-ring (Scheme 4.1).  The acetylenic 
linker offers unique advantages as it projects the B-ring deeper into a large 
hydrophobic cavity in PLA’s target, DHFR, while the small, linear projection of the 
alkyne allows it to pass through a narrow channel in the enzyme.   
  
 In developing this class of inhibitors, the importance of propargyl substitution has 
shown itself to be critical with unsubstituted, mono-methylated, and di-methylated 
derivatives showing strong effects on organism-specific potency,21 selectivity over the 
human DHFR,22 metabolic stability,23 and NADPH binding.24  Various propargyl 
Scheme 4.1. PLA Synthesis:  Benefits of an Updated Synthesis 
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substitutions are required to probe the hydrophobic pocket of DHFR to properly 
determine structure-activity relationships (SAR).   
 We had previously developed25 a route (Scheme 4.1) to the acetylenic component 
of PLAs based on a Wittig homologation of biaryl aldehydes 1 or methyl ketones 2 to 
produce the unsubstituted or mono-methylated intermediates 3 and 4 respectively; the 
geminal-dimethyl substitution 5 was prepared via subsequent enolate alkylation.  
Homologation of the phenylacetaldehydes with the Ohira-Bestmann26 reagent 
generated terminal alkyne building blocks 6-8 that were subjected to Sonogashira 
coupling with the 2,4-diaminopyrimidine A ring to generate PLAs.  There are several 
drawbacks to the homologation method: 1) Divergence occurs at the beginning of the 
synthesis leading to synthetic redundancies to generate slightly modified PLAs for 
SAR, 2) use of the expensive Ohira-Bestmann reagent required to build alkynes, 
instead of intermolecular alkyne addition, and 3) alkyne homologation often leads to 
base-mediated alkyne isomerization to allene, lowering yields.  
 We have been interested in developing an alternative route to terminal acetylenes 
that would allow access to various propargyl substitutions from a common starting 
material.  We desired a route that would begin with nucleophilic alkyne addition to 
biaryl aldehydes 1 to produce propargyl alcohols 9 (Scheme 4.1). Divergence from 9 
via propargyl alcohol displacement would generate the unbranched PLAs 6 via 
deoxygenation and the mono-methyl (7) and dimethyl PLAs (8) via nucleophilic 
methylation.   
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4.4 Previous Methods for Deoxygenation of Propargyl Alcohols  
 Trifluoroacetic acid is often used to activate the propargyl alcohols with hydride as 
the reductant; however isomerization of the propargyl cation to the allenyl cation often 
complicates the reaction.27,28  Nicholas employed Co2(CO8) to stabilize the propargyl 
cation and reduce allene formation.14,15,17  Lewis-acid mediated deoxygenation of 
propargyl alcohols typically utilizes boron trifluoride etherate and triethylsilane as the 
hydride source.29   Other Lewis acids have included Bi(OTf)3, Ca(Ntf2)2,31 InBr3,32 and 
NaAuCl4.33  Heterocycles and silyl-protected terminal alkynes are uncommon 
functionalities in the reported examples.   
 
4.5 Previous Methods for Methylation of Propargyl Alcohols 
 Nucleophilic methyl additions to propargyl alcohols are sparse in the literature, and 
complicated by a lack of substrate diversity and the need for various ligands (Scheme 
4.3).34,35  Moreover, nucleophilic methyl additions to arylalkynyl carbinols are 
Scheme 4.2 Selected Examples of Propargyl Alcohol Deoxygenation 
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practically unknown in the literature.  A single report described methyl magnesium 
bromide displacement of an arylalkynyl carbinol previously reacted with a ruthenium-
based fullerene ligand to generate a stable ruthenium- allenylidene complex (Scheme 
4.3).36 Additionally, PLAs often possess a basic heterocyclic C-ring that could limit the 
ability to effect such direct methylations.  Previous members of the Wright lab had 
utilized methodology first reported by Reetz37,38 to effect a late-stage geminal 
dimethylation in the total synthesis of Frondosin B.39  We were interested in 
repurposing Reetz’s reagent, a pre-mixed solution of dimethyl zinc and titanium 
tetrachloride, for our propargyl methylation needs. Herein, we describe an efficient 
series of propargylic substitution reactions compatible with the heterocyclic 
functionality that can be used to generate a homologous series of propargylic variants 
from a common starting material. 
 
 
 
Scheme 4.3 Selected Examples of Propargyl Alcohol Methylation 
104 
 
4.6 Modified Synthesis Results 
 Several commercially or readily available m-bromobenzaldehydes were directly 
converted to a variety of heterobiaryl aldehydes by Suzuki cross-coupling with a 
suitable boronic acid.  The aryl propargyl alcohols 10a-k were prepared by 
nucleophilic addition of trimethylsilylacetylene to the aryl aldehyde.  Treatment of the 
alcohols with an excess of boron trifluoride etherate and triethylsilane led to the 
reduced methylene derivatives as an unexpected mixture of TMS-, TES- and 
desilylated terminal acetylenes (Scheme 4.4).  The reaction was compatible with 
several nitrogenous heterocycles with the exception of pyrimidine (11f, 11h), where 
there was competitive hydride reduction of the heterocycle.  In the cases of silyl-alkyne 
mixtures of deoxygenated products the crude reaction mixture was subjected to a mild 
deprotection involving either a silver/cyanide mediated40 hydrolysis or a less toxic 
equimolar mixture41 of n-Bu4NF and CH3COOH to convert all species to the desired 
terminal alkyne. There is no precedent, to our knowledge, for the silyl exchange 
reaction that occurs in the reduction process. 
Scheme 4.4 Deoxygenation of Propargyl Alcohols 
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Treatment of the secondary alcohols with dimethylzinc42 (Scheme 4.5) in the 
presence of titanium tetrachloride led to direct formation of the methyl branched 
systems in good overall yields.  Surprisingly, only the o-methoxy substituted 12b saw 
significant allene formation, possibly due to the lack of aryl stabilization of the 
propargyl cation intermediate.  Desilylations of the terminal acteylenes were 
accomplished using silver nitrate and potassium cyanide.  To generate geminal 
dimethyl substitution at the propargyl position the secondary propargyl alcohols were 
oxidized to their corresponding ketones with manganese dioxide.  Methyl magnesium 
bromide addition to propargyl ketones generated tertiary alcohols which were 
subjected to the same Reetz chemistry to give geminal dimethyl variants.  Desilylation 
was accomplished using potassium carbonate in alcoholic solvent.  These conditions 
were not amenable to the mono-methylated compounds as allene isomerization was 
observed.   
Scheme 4.5 Methylation of Propargyl Alcohols 
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In summary, these methods allow for ready access to a series of 3-aryl 
propynes with both unsubstituted and branched propargylic carbons. Additional 
stabilization of the putative aryl substituted propargyl cation by suitably placed donor 
groups on the aromatic ring improves the overall efficiency of the reaction.  These 
direct substitution reactions were sufficiently mild to allow the incorporation of the wide 
range of nitrogenous heterocycles in the substrate. In addition, there is evidence that 
the basic heterocycle plays a role in the facility of the reduction process, an effect that 
can be mimicked by the addition of exogenous pyridine to the reaction.  These direct 
methods provide for the preparation of the series of differentially substituted 1-aryl 
propynes from readily available propargyl alcohols by direct reduction or substitution 
of the readily ionized hydroxyl group. 
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4.7 Experimental Data 
The 1H and 13C NMR spectra were recorded on Bruker instruments at 500 MHz. 
Chemical shifts are reported in ppm and are referenced to residual CHCl3 solvent; 
7.24 and 77.23 ppm for 1H and 13C, residual solvent MeOH; 4.78, 3.31 and 49.15 ppm 
respectively. The high-resolution mass spectrometry was provided by the Notre Dame 
Mass Spectrometry Laboratory and University of Connecticut Mass Spectrometry 
Laboratory using AccuTOF mass spectrometer and/or using DART source. IR data 
were obtained using Alpha diamond ATR probe. TLC analyses were performed on 
Sorbent Technologies silica gel HL TLC plates. All glassware was oven-dried and 
allowed to cool under an argon atmosphere. Anhydrous dichloromethane, and 
tetrahydrofuran were used directly from Baker Cycle-Tainers. All reagents were used 
directly from commercial sources unless otherwise stated. Boronic acids for Suzuki 
coupling were purchased from Frontier Scientific, Inc. 
General Procedure for Alkyne Addition 
A 50 mL flask with stir bar was flame dried under argon. Ethynyltrimethyl silane was 
added to THF (2M) at 0 °C and stirred for two minutes. Isopropyl magnesium chloride 
was added dropwise and stirred initially at 0 °C for 30 minutes followed by another 30 
minutes at room temperature. The grey colored Grignard reagent was cooled to 0 °C 
and the aldehyde in THF (0.1M) was added dropwise for 5 minutes. The reaction was 
followed by TLC and quenched with sat. NH4Cl. The aqueous layer was extracted with 
ether (3x). The combined organic layers were dried with MgSO4, filtered, and 
evaporated. The crude compound was pre-absorbed onto silica gel and purified by 
column chromatography. 
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1-(2-methoxy-5-(pyridin-4-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-1-ol (10a) 
According to the general nucleophilic addition, ethynyltrimethyl silane (6.6mmol, 
0.93mL) in THF (2M, 3.29 mL) and isopropyl magnesium chloride (2M, 3.3mL) was 
stirred.  At 0 °C was added the aldehyde (5.06 mmol, 1.07 g) in THF (0.1M, 50.6mL).  
Following the general workup and flash chromatography (SiO2, 40 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a white solid (1.48 g, 94%): TLC 
Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 5.7 Hz, 2H), 
7.91 (d, J = 2.2 Hz, 1H), 7.58 (dd, J = 8.5, 2.2  Hz, 1H), 7.44 (d, J = 6.0 Hz, 2H), 6.98 
(d, J = 8.5 Hz, 1H), 5.77 (s, 1H), 3.92 (s, 3H), 0.19 (s, 9H); 13C NMR (125 MHz, CDCl3) 
δ 158.0, 150.3, 148.0, 130.5, 129.8, 128.3, 127.0, 121.2, 111.6, 104.7, 91.5, 61.0, 
56.0, 0.1.; IR (neat cm-1) 3139, 2977, 2868, 2165, 1562, 1504, 1228, 1011; HRMS 
(DART, M+ + H) m/z 312.1393 (calculated for C18H21NO2Si, 312.1420). 
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1-(2-methoxy-5-(pyrimidin-5-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-1-ol (10b) 
According to the general nucleophilic addition, ethynyltrimethyl silane (3.55mmol, 0.50 
mL) in THF (2M, 1.78 mL) and isopropyl magnesium chloride (2M, 3.55 mmol, 1.78 
mL) was stirred. At 0 °C was added the aldehyde (2.37 mmol, 0.51g) in THF (0.1M, 
23.6 mL). Following the general workup and flash chromatography (SiO2, 20 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a white solid (0.7 g, 95%): TLC Rf 
= 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 8.90 (s, 2H), 7.85 
(s, 1H), 7.52 (d, J = 10.7 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 5.77 (s, 1H), 3.93 (s, 3H), 
0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 157.9, 157.2, 154.6, 134.0, 130.1, 128.4, 
126.9, 126.9, 112.0, 104.2, 91.9, 61.1, 56.1, 0.1; IR (neat cm-1) 3177, 3010, 2837, 
2164, 1608, 1308, 1059; HRMS (DART, M+ + H) m/z 313.1391 (calculated for 
C17H20N2O2Si, 312.1372). 
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1-(2-methoxy-5-(pyrazin-2-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-1-ol (10c) 
According to the general nucleophilic addition, ethynyltrimethyl silane (1.45 mmol, 0.2 
mL) in THF (2M, 0.72 mL) and isopropyl magnesium chloride (2M, 0.72 mL) was 
stirred. At 0 °C was added the aldehyde (0.9 mmol, 0.2 g) in THF (0.1M, 9.7mL).  
Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a white solid (0.27 g, 95%): TLC 
Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 8.57 (s, 1H), 
8.43 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.2 Hz, 1H), 8.01 (dd, J = 8.6, 2.3 Hz, 1H), 7.01 
(d, J = 8.6 Hz, 1H), 5.75 (s, 1H), 3.94 (s, 3H), 0.20 (s, 9H). 13C NMR (125 MHz, CDCl3) 
δ 158.6, 152.5, 144.3, 142.4, 141.7, 129.6, 129.1, 128.7, 127.0, 111.6, 104.5, 91.7, 
61.5, 56.1, 0.1. IR (neat cm-1) 3055, 2980, 2884, 2847, 1913, 1675, 1604, 1414, 1272, 
1166, 1112, 1010, 825; HRMS (DART, M+ + H) m/z 313.1394 (calculated for 
C17H20N2O2Si, 312.1372). 
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1-(3-methoxy-5-(pyridin-4-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-1-ol (10d) 
According to the general nucleophilic addition, ethynyltrimethyl silane (2.1 mmol, 0.3 
mL) in THF (2M, 1.0 mL) and isopropyl magnesium chloride (2M, 1.0 mL) was stirred. 
At 0 °C was added the aldehyde (1.7 mmol, 0.4 g) in THF (0.1M, 17.4 mL).  Following 
the general workup and flash chromatography (SiO2, 20 g, 3%MeOH/CH2Cl2), the title 
alkynol was obtained as a brownish oil (0.51 g, 94%): TLC Rf = 0.1 (3%MeOH/CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.59 (s, 2H), 7.46 (d, J = 4.5 Hz, 2H), 7.38 (s, 1H), 7.19 
(s, 1H), 7.07 (s, 1H), 5.50 (s, 1H), 3.85 (s, 3H), 0.18 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 160.5, 150.1, 148.5, 143.5, 139.7, 122.0, 118.0, 113.1, 112.7, 105.4, 91.7, 
64.7, 55.7, 0.0; IR (neat cm-1) 3153, 2958, 2899, 2837, 2170, 1648, 1550, 1325, 1217, 
1049; HRMS (DART, M+ + H) m/z 312.1434 (calculated for C18H21NO2Si, 312.1420). 
 
1-(3,4-dimethoxy-5-(pyridin-4-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-1-ol (10e) 
According to the general nucleophilic addition, ethynyltrimethyl silane (3.79 mmol, 
0.54 mL,) in THF (2M, 1.9 mL) and isopropyl magnesium chloride (2M, 1.9 mL) was 
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stirred. At 0 °C was added the aldehyde (2.5 mmol, 0.6g) in THF (0.1M, 25.2 mL).  
Following the general workup and flash chromatography (SiO2, 30 g, 50% 
3%MeOH/CH2Cl2), the title alkynol was obtained as a colorless oil (0.82g, 95%): TLC 
Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.57 (d, J = 4.9 Hz, 2H), 
7.45 (d, J = 6.0 Hz, 2H), 7.21 (d, J = 1.7 Hz, 1H), 7.09 (d, J = 1.8 Hz, 1H), 5.45 (s, 
1H), 3.91 (s, 3H), 3.59 (s, 3H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 153.4, 
149.5, 146.7, 146.4, 137.3, 132.6, 124.3, 120.4, 111.7, 105.5, 91.8, 64.6, 61.0, 56.2, 
0.0;  IR (neat cm-1) 3085, 3009, 2964, 2821, 2162, 1642, 1410, 1241, 1134, 1049, 
828; HRMS (DART, M+ + H) m/z 342.1516 (calculated for C19H23NO3Si, 342.1525). 
 
1-(7-(pyridin-4-yl) benzo[d][1,3] dioxol-5-yl)-3-(trimethylsilyl) prop-2-yn-1-ol (10f) 
According to the general nucleophilic addition, ethynyltrimethyl silane (3.78 mmol, 
0.53 mL) in THF (0.53 mL) and isopropyl magnesium chloride (2M, 1.9 mL) was 
stirred. At 0 °C was added the aldehyde (1.26 mmol, 0.3g) in THF (0.1M, 12.6 mL).  
Following the general workup and flash chromatography (SiO2, 15 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a yellow hygroscopic solid (0.41 
g, 99%): TLC Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 
4.3 Hz, 2H), 7.61 (d, J = 5.8 Hz, 2H), 7.28 (s, 1H), 7.09 (s, 1H), 6.05 (s, 2H), 5.42 (s, 
1H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 150.0, 148.8, 145.6, 143.6, 135.9, 
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122.3, 119.2, 119.0, 108.3, 105.4, 101.8, 91.6, 64.5, 0.0; IR (neat cm-1) 3140, 2958, 
2896, 2170, 1639, 1600, 1402, 1248, 1195, 1044, 1002, 824; HRMS (DART, M+ + H) 
m/z 326.1223 (calculated for C18H19NO3Si, 326.1212). 
 
1-(7-(pyrimidin-5-yl) benzo[d][1,3] dioxol-5-yl)-3-(trimethylsilyl) prop-2-yn-1-ol 
(10g) 
According to the general nucleophilic addition, ethynyltrimethyl silane (0.9 mmol, 0.14 
mL) in THF (2M, 0.5 mL) and isopropyl magnesium chloride (2M, 0.99 mmol, 0.5 mL 
was stirred. At 0 °C was added the aldehyde (0.66 mmol, 0.15 g) in THF (0.1M, 6.6 
mL).  Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a light yellow solid (0.21 g, 96%): 
TLC Rf = 0.1 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 9.05 (s, 
2H), 7.24 (s, 1H), 7.10 (s, 1H), 6.07 (s, 2H), 5.42 (s, 1H), 0.20 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 157.5, 155.5, 148.9, 145.5, 136.0, 129.8, 118.8, 115.3, 108.3, 104.8, 
102.0, 92.3, 64.7, 0.0; IR (neat cm-1) 3189, 2955, 2899, 2172, 1606, 1409, 1249, 1041, 
1006, 837; HRMS (DART, M+ + H) m/z 327.1190 (calculated for C17H18N2O3Si, 
327.1165). 
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1-(2-methoxy-5-(1-methyl-1H-imidazol-5-yl) phenyl)-3-(trimethylsilyl) prop-2-yn-
1-ol (10h) 
According to the general nucleophilic addition, ethynyltrimethyl silane (2.0 mmol, 0.28 
mL) in THF (1.0 mL) and isopropyl magnesium chloride (2M, 2.0 mmol, 1.0 mL) was 
stirred. At 0 °C was added the aldehyde (1.66 mmol, 0.36 g) in THF (0.1M, 16.6 mL). 
Following the general workup and flash chromatography (SiO2, 10 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a light yellow solid (0.49 g, 94%): 
TLC Rf = 0.03 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 2.1 Hz, 
1H), 7.45 (s, 1H), 7.27 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (s, 1H), 6.93 (d, J = 8.5 Hz, 1H), 
5.76 (s, 1H), 3.88 (s, 3H), 3.60 (s, 3H), 0.15 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
156.7, 138.8, 133.2, 129.9, 129.6, 128.5, 127.5, 122.3, 111.3, 105.0, 90.9, 60.5, 55.9, 
32.6, 0.1; IR (neat cm-1) 3113, 2957, 2899, 2837, 2167, 1488, 1279, 1040, 838; HRMS 
(DART, M+ + H) m/z 315.1532 (calculated for C17H22N2O2Si, 315.1529). 
 
 
115 
 
 
1-(5-(3,5-dimethylisoxazol-4-yl)-2-methoxyphenyl)-3-(trimethylsilyl) prop-2-yn-
1-ol (10i) 
According to the general nucleophilic addition, ethynyltrimethyl silane (4.1 mmol, 0.6 
mL) in THF (2M, 2.0 mL) and isopropyl magnesium chloride (2M, 4.1mmol, 2.0 mL) 
was stirred. At 0 °C was added the aldehyde (2.72 mmol, 0.63 g) in THF (0.1M, 27.2 
mL). Following the general workup and flash chromatography (SiO2, 20 g, 
3%MeOH/CH2Cl2), the title alkynol was obtained as a colorless oil (0.86 g, 96%): TLC 
Rf = 0.4 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.17 (d, J = 
8.1 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 5.76 (d, J = 5.4 Hz, 1H), 3.90 (s, 3H), 2.38 (s, 
3H), 2.24 (s, 3H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 164.9, 158.7, 156.2, 
130.2, 129.2, 128.9, 122.7, 116.1, 111.3, 104.6, 91.0, 60.5, 55.8, 11.5, 10.8, -0.1; IR 
(neat cm-1) 3038, 2923, 2862, 2724, 1682, 1601, 1245, 1176, 1120, 1014, 825; HRMS 
(DART, M+ + H) m/z 330.1528 (calculated for C18H23NO3Si, 330.1525). 
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1-(5-(pyridin-4-yl) thiophen-2-yl)-3-(trimethylsilyl) prop-2-yn-1-ol (10j) 
According to the general nucleophilic addition, ethynyltrimethyl silane (2.6 mmol, 0.4 
mL) in THF (2M, 1.3 mL) and isopropyl magnesium chloride (2M, 2.6 mmol, 1.3 mL) 
was stirred. At 0 °C was added the aldehyde (2.2 mmol, 0.41g) in THF (0.1M, 21.6 
mL). Following the general workup and flash chromatography (SiO2, 20 g, 
3%MeOH/CH2Cl2), the title alkynol  was obtained as a brown solid (0.6 g, 95%): TLC 
Rf = 0.2 (3%MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 6.2 Hz, 2H), 
7.41 (d, J = 6.2 Hz, 2H), 7.33 (d, J = 3.7 Hz, 1H), 7.14 (d, J = 4.4 Hz, 1H), 5.65 (s, 
1H), 0.19 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 150.1, 147.7, 141.9, 141.1, 126.7, 
125.3, 119.9, 104.4, 91.3, 60.6, -0.1; IR (neat cm-1) 3181, 3017, 2112, 1592, 1494, 
1414, 1219, 991, 800; HRMS (DART, M+ + H) m/z 288.0901 (calculated for 
C15H17NOSSi, 288.0878). 
General Procedure for Propargyl Methylation 
To a 100 mL flame dried flask under argon was added CH2Cl2 (1M) at room 
temperature and cooled to 0 °C. TiCl4 (1M in toluene, 1 eq) was added followed by 
dimethyl zinc (1.2 M in toluene, 2 eq) and stirred at 0 °C for 30 minutes. To the yellow 
heterogeneous mixture, alkynol (1eq, in 0.1 M CH2Cl2) was added dropwise for 10 
min. TLC analysis was performed on a small aliquot quenched with MeOH. After ~1 
h, the reaction was stopped by a slow dropwise addition of MeOH. Care should be 
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taken to avoid frothing and addition of MeOH continued until the reaction turns into a 
homogeneous yellow solution. The crude mixture was stirred at room temperature for 
5 minutes and pushed through a plug of silica gel and the solvent was evaporated. To 
deprotect the TMS alkyne, the crude mixture was dissolved in EtOH (0.2M) and stirred 
for 30 min with AgNO3 (3 eq, in 1.5M water). KCN (10 eq) dissolved in H2O (10M) was 
added slowly and stirred for 1h. The reaction mixture was diluted with EtOAc, washed 
with water, and dried with MgSO4. The solvent was evaporated, the crude mixture was 
pre-absorbed onto silica gel, and column chromatography was carried out with 3% 
MeOH in CH2Cl2 to afford propargyl-methylated alkynes. 
 
4-[5-(1-Methyl-prop-2-ynyl)-thiophen-2-yl]-pyridine (12j) 
According to the general methylation protocol, alkynol (0.52 mmol, 0.15 g) in CH2Cl2 
(0.1M) was added to the pre-mixed solution of TiCl4 (0.52 mmol, 1.0 mL) and 
dimethylzinc (1.04 mmol, 1.60 mL) in CH2Cl2 (1M). Following the general workup and 
deprotection, the crude mixture was purified by flash chromatography (SiO2, 5 g, 1:1 
EtoAc/hexane) to give the methylated alkyne as a yellow solid (0.17 g, 65%): TLC Rf 
= 0.8 (1:1 EtoAc/hexane); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 4.6 Hz, 2H), 7.48 
– 7.41 (m, 2H), 7.35 (d, J = 3.7 Hz, 1H), 7.03 (dd, J = 3.6, 1.0 Hz, 1H), 4.06 (qd, J = 
6.9, 2.1 Hz, 1H), 2.36 (d, J = 2.5 Hz, 1H), 1.65 (d, J = 7.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 150.3, 148.5, 141.4, 139.5, 125.3, 125.0, 119.5, 85.6, 70.5, 27.4, 24.0; IR 
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(neat cm-1) 3198, 2984, 2934, 1594, 1460, 1414, 1220, 991, 802, 690, 525; HRMS 
(DART, M+ + H) m/z 214.0705 (calculated for C13H12NS, 214.0690). 
Tertiary propargyl alcohol formation from secondary propargyl alcohol.  The 
secondary propargyl alcohol was added in dichloromethane to a dried round bottom 
flask fitted with a stir bar and dried MnO2 (20 equiv).  Once complete by TLC, the 
reaction mixture was filtered through celite and solvent removed in vacuo.  The 
residue was brought up in THF, placed under argon, and methyl magnesium bromide 
(3.0 M in Et2O, 1.5 equiv) was added via syringe.  Once complete by TLC, saturated 
ammonium chloride was added.  The product was extracted 3x with EtOAc, washed 
with brine, dried over sodium sulfate, filtered, and dried in vacuo.  The tertiary alcohol 
was used with no further purification. 
 
4-[3-(1,1-Dimethyl-prop-2-ynyl)-4-methoxy-phenyl]-pyridine (13a) 
The tertiary alcohol (0.15 g, 0.461 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a white solid (0.08 g, 53% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 8.66 (s, 2H), 8.07 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 
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7.55 – 7.48 (m, 2H), 7.02 (d, J = 8.4 Hz, 1H), 3.94 (s, 3H), 2.47 (s, 1H), 1.77 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 158.9, 150.3, 148.3, 133.9, 130.1, 126.8, 121.4, 112.5, 
91.4, 70.4, 55.6, 36.1, 29.0; IR (neat cm-1) 3295, 2972, 2934, 1597, 1487, 1283, 1253, 
1221, 1081, 1024, 808, 637; HRMS (DART) calcd for C17H17NO  [M+H]+: 252.1368, 
obs. 252.1326. 
 
5-[3-(1,1-Dimethyl-prop-2-ynyl)-4-methoxy-phenyl]-pyrimidine (13b) 
The tertiary alcohol (0.15 g, 0.459 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a white solid (0.07 g, 47% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 9.30 – 9.16 (m, 1H), 9.01 (s, 2H), 8.00 (d, J = 2.3 
Hz, 1H), 7.49 (dd, J = 8.4, 2.3 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 3.95 (s, 3H), 2.47 (s, 
1H), 1.77 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 158.7, 156.9, 154.6, 134.4, 126.9, 
126.8, 126.3, 112.8, 91.3, 70.7, 70.7, 55.6, 36.2, 29.0; IR (neat cm-1) 3290, 2970, 
2931, 1606, 1550, 1500, 1389, 1358, 1286, 1252, 1223, 1080, 1022, 895, 815, 726, 
627; HRMS (DART) calcd for C16H16N2O  [M+H]+: 253.1341, obs. 253.1316. 
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2-[3-(1,1-Dimethyl-prop-2-ynyl)-4-methoxy-phenyl]-pyrazine (13c) 
The tertiary alcohol (0.15 g, 0.459 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a white solid (0.08 g, 55% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 9.03 (s, 1H), 8.62 (s, 1H), 8.47 (s, 1H), 8.42 (d, J = 
2.0 Hz, 1H), 7.95 (dd, J = 8.5, 2.0 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 3.96 (s, 3H), 2.46 
(s, 1H), 1.78 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.5, 153.1, 144.2, 142.2, 134.0, 
128.6, 127.1, 126.7, 112.4, 91.4, 70.2, 55.6, 36.0, 29.1; IR (neat cm-1) 3292, 2971, 
2932, 1605, 1503, 1427, 1279, 1252, 1143, 1078, 1025, 816, 634; HRMS (DART) 
calcd for C16H16N2O  [M+H]+: 253.1341, obs. 253.1322. 
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4-[3-(1,1-Dimethyl-prop-2-ynyl)-5-methoxy-phenyl]-pyridine (13d) 
The tertiary alcohol (150 mg, 0.461 mmol) was subjected to the general procedure for 
methylation. Once completed, the dried residue isolated from silica plug was dissolved 
in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until complete by TLC. 
The title compound was purified via column chromatography (SiO2, 1:1 ethyl 
acetate/hexanes) and isolated as a white solid (0.08 g, 50% 2 steps); 1H NMR (500 
MHz, Chloroform-d) δ 8.85 – 8.54 (m, 2H), 7.63 – 7.48 (m, 2H), 7.44 (d, J = 1.6 Hz, 
1H), 7.23 (d, J = 2.0 Hz, 1H), 7.03 (d, J = 1.9 Hz, 1H), 3.91 (s, 3H), 2.42 (s, 1H), 1.67 
(s, 6H). 13C NMR (126 MHz, CDCl3) δ 160.3, 150.4, 149.1, 148.7, 139.8, 122.0, 117.1, 
112.7, 110.6, 90.7, 70.5, 55.6, 36.2, 31.7; IR (neat cm-1) 3288, 2974, 2932, 1592, 
1549, 1451, 1405, 1322, 1264, 1049, 818, 642; HRMS (DART) calcd for C17H17NO  
[M+H]+: 252.1368, obs. 252.1407. 
 
4-[5-(1,1-Dimethyl-prop-2-ynyl)-2,3-dimethoxy-phenyl]-pyridine (13e) 
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The tertiary alcohol (150 mg, 0.422 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a yellow solid (0.08 g, 56% 2 steps) (; 1H 
NMR (500 MHz, Chloroform-d) δ 8.68 (s, 2H), 7.52 (d, J = 4.2 Hz, 2H), 7.24 (d, J = 
1.7 Hz, 1H), 7.12 (d, J = 1.8 Hz, 1H), 3.96 (s, 3H), 3.64 (s, 3H), 2.40 (s, 1H), 1.65 (s, 
6H). 13C NMR (126 MHz, CDCl3) δ 153.0, 149.7, 146.5, 145.4, 142.9, 132.6, 124.4, 
118.9, 111.1, 90.8, 70.3, 61.0, 56.2, 36.0, 31.8; IR (neat cm-1) 3286, 2973, 2933, 1594, 
1547, 1481, 1462, 1405, 1278, 1240, 1146, 1042, 1005, 827, 645; HRMS (DART) 
calcd for C18H19NO2  [M+H]+: 282.1494, obs. 282.1504. 
 
4-[6-(1,1-Dimethyl-prop-2-ynyl)-benzo[1,3] dioxol-4-yl]-pyridine (13f) 
The tertiary alcohol (150 mg, 0.442 mmol) was subjected to the general procedure for 
methylation. Once completed, the dried residue isolated from silica plug was dissolved 
in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until complete by TLC. 
The title compound was purified via column chromatography (SiO2, 1:1 ethyl 
acetate/hexanes) and isolated as an off-white solid (0.07 g, 46% 2 steps); 1H NMR 
(500 MHz, Chloroform-d) δ 8.72 (s, 2H), 7.69 (d, J = 5.2 Hz, 2H), 7.42 – 7.31 (m, 1H), 
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7.12 (d, J = 1.8 Hz, 1H), 6.08 (s, 2H), 2.42 (s, 1H), 1.64 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 150.3, 148.6, 144.2, 143.6, 141.4, 122.4, 119.0, 117.6, 107.3, 101.6, 90.8, 
70.4, 70.4, 35.9, 31.9; IR (neat cm-1) 3291, 3030, 2928, 1969, 1597, 1544, 1474, 1403, 
1221, 1043, 943, 823, 651; HRMS (DART) calcd for C17H15NO2  [M+H]+: 266.1181, 
obs. 266.1208. 
 
5-[6-(1,1-Dimethyl-prop-2-ynyl)-benzo[1,3] dioxol-4-yl]-pyrimidine (13g) 
The tertiary alcohol (150 mg, 0.441 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a yellow solid (0.08 g, 51% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 9.20 (s, 1H), 9.12 (s, 2H), 7.32 (d, J = 1.8 Hz, 1H), 
7.13 (d, J = 1.8 Hz, 1H), 6.09 (s, 2H), 2.42 (s, 1H), 1.64 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 157.3, 155.4, 148.5, 143.9, 141.7, 130.0, 117.0, 114.9, 107.1, 101.6, 90.4, 
70.4, 35.8, 31.7; IR (neat cm-1) 3295, 2977, 2167, 1551, 1408, 1262, 1178, 1038, 940, 
855, 724, 632; HRMS (DART) calcd for C16H14N2O2  [M+H]+: 267.1133, obs. 267.1109. 
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5-[3-(1,1-Dimethyl-prop-2-ynyl)-4-methoxy-phenyl]-1-methyl-1H-imidazole (13h) 
The tertiary alcohol (150 mg, 0.457 mmol) was subjected to the general procedure for 
methylation. Once completed, the dried residue isolated from silica plug was dissolved 
in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until complete by TLC. 
The title compound was purified via column chromatography (SiO2, 1:1 ethyl 
acetate/hexanes) and isolated as a yellow solid (0.07 g, 48% 2 steps); 1H NMR (500 
MHz, Chloroform-d) δ 7.77 (d, J = 2.2 Hz, 1H), 7.53 (s, 1H), 7.29 (dd, J = 8.3, 2.3 Hz, 
2H), 7.08 (s, 1H), 6.98 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H), 3.68 (s, 3H), 2.42 (s, 1H), 1.74 
(s, 6H). 13C NMR (126 MHz, CDCl3) δ 157.5, 138.7, 133.5, 133.3, 128.3, 128.3, 127.8, 
127.5, 121.8, 112.0, 91.4, 70.1, 55.4, 35.9, 32.5, 28.8; IR (neat cm-1) 3288, 2927, 
2853, 1767, 1713, 1492, 1366, 1252, 1196, 1080, 1024, 817, 637; HRMS (DART) 
calcd for C16H18N2O  [M+H]+: 255.1497, obs. 255.1523. 
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4-[3-(1,1-Dimethyl-prop-2-ynyl)-4-methoxy-phenyl]-3,5-dimethyl-isoxazole (13i) 
The tertiary alcohol (150 mg, 0.437 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a yellow solid (0.08 g, 54% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 7.66 (d, J = 2.2 Hz, 1H), 7.15 (dd, J = 8.3, 2.2 Hz, 
1H), 6.98 (d, J = 8.3 Hz, 1H), 3.92 (s, 3H), 2.44 (s, 3H), 2.42 (s, 1H), 2.31 (s, 3H), 1.74 
(s, 6H). 13C NMR (126 MHz, CDCl3) δ 164.8, 158.9, 157.0, 133.4, 128.7, 128.4, 122.3, 
116.4, 112.1, 91.4, 70.0, 55.3, 35.9, 28.9, 11.6, 10.9; IR (neat cm-1) 3288, 2970, 2930, 
1603, 1505, 1453, 1358, 1251, 1218, 1080, 1026, 819, 642; HRMS (DART) calcd for 
C17H19NO2  [M+H]+:  270.1494, obs. 270.1477. 
 
4-[5-(1,1-Dimethyl-prop-2-ynyl)-thiophen-2-yl]-pyridine (13j) 
The tertiary alcohol (150 mg, 0.498 mmol) was subjected to the general procedure for 
methylation.  Once completed, the dried residue isolated from silica plug was 
dissolved in MeOH and K2CO3 (2 equiv) added.  The reaction was stirred until 
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complete by TLC. The title compound was purified via column chromatography (SiO2, 
1:1 ethyl acetate/hexanes) and isolated as a yellow solid (0.07 g, 46% 2 steps); 1H 
NMR (500 MHz, Chloroform-d) δ 8.60 (s, 2H), 7.46 (d, J = 5.1 Hz, 2H), 7.35 (d, J = 
3.8 Hz, 1H), 7.07 (d, J = 3.8 Hz, 1H), 2.41 (s, 1H), 1.73 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 154.2, 150.3, 141.5, 139.1, 124.9, 124.3, 119.6, 89.5, 69.7, 34.0, 32.4; IR 
(neat cm-1) 3284, 2987, 2967, 1594, 1495, 1412, 1221, 991, 808, 652; HRMS (DART) 
calcd for C14H13NS  [M+H]+: 228.0847, obs. 228.0867. 
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